Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
Analyzing specific SNPs helps select cancer patients for antibody therapy by predicting responsiveness and clinical outcomes, addressing the need for personalized treatment selection in gastroesophageal cancer.
Patent Information
- Application Number
- KR1020267035435
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-04-15
- Filing Date
- 2016-04-13
- Publication Date
- 2026-11-10
AI Technical Summary
There is a need for tests to measure a patient's suitability for antibody therapy, particularly for CLDN18.2-positive gastroesophageal cancer, as the discrepancy in antigen-positive tumors suggests additional factors related to treatment outcomes, requiring careful patient selection for therapies like IMAB362.
A method involving the analysis of specific single-nucleotide polymorphisms (SNPs) such as FCGR2A rs1801274, MUC1 rs4072037, IL-10 rs1800896, DNMT3A rs1550117, SMAD4 rs12456284, EGF rs4444903, CDH1 rs16260, ERCC1 rs11615, and FCGR3A rs396991 to determine a patient's responsiveness to antibody therapy and predict clinical outcomes.
The method allows for accurate selection of cancer patients who are likely to respond to antibody therapy and experience progression-free survival, reducing the risk of non-response and poor clinical outcomes by identifying suitable therapeutic regimens.
Smart Images

Figure PAT00036_ABST
Abstract
Description
Technology Field
[0001] The present invention generally relates to a method and composition for predicting the therapeutic efficacy of cancer treatments and the prognosis of cancer. The present invention discloses markers that are useful as prognostic markers for cancer, each associated with a desirable or undesirable outcome in a specific cancer treatment. A method comprising such markers is disclosed for predicting the effect of cancer treatment and predicting clinical outcomes for cancer patients. Background Technology
[0002] Gastric and esophageal cancer (gastroesophageal; GE) are among the malignancies with the most unmet medical needs. Gastric cancer is the second leading cause of death worldwide. The incidence of esophageal cancer has increased over the past few decades, and the overall 5-year survival rate for GE is 20–25%, which is associated with significant side effects despite the aggressiveness of established standard treatments. Patients suffering from this type of cancer have high medical needs, and innovative drugs are required.
[0003] The tight-junction molecule Claudin-18 allotype 2 (CLDN18.2) is a cancer-associated splice variant of Claudin-18 [Niimi, T., et al., Mol Cell Biol, 2001. 21(21): p. 7380-90; Tureci, O., et al., Gene, 2011. 481(2): p. 83-92]. CLDN18.2 is a 27.8 kDa transmembrane protein containing four transmembrane domains with two small extracellular loops (Loop 1 surrounded by hydrophobic regions 1 and 2; Loop 2 surrounded by hydrophobic regions 3 and 4). CLDN18.2 is a highly selective gastric lineage antigen and is expressed exclusively in short-lived differentiated gastric epithelial cells and is not detected in any other normal human tissue. The above antigen is ectopically expressed at significant levels in various types of human cancer, including gastroesophageal and pancreatic cancer [Sahin, U., et al., Clin Cancer Res, 2008. 14(23): p. 7624-34]. In addition, the CLDN18.2 protein is often detected in lymph node metastasis and distant metastasis of gastric cancer. CLDN18.2 appears to be involved in the proliferation of CLDN18.2-positive tumor cells, as downregulation of the target by siRNA technology inhibits the proliferation of gastric cancer cells.
[0004] IMAB362 is a chimeric monoclonal antibody of the IgG1 subtype against CLDN18.2. IMAB362 recognizes the first extracellular domain of CLDN18.2 with high affinity and specificity and does not bind to other members of the Claudin family, including splice variant 1, which is closely related to Claudin 18 (CLDN18.1).
[0005] In human xenografts expressing CLDN18.2, survival benefits and tumor regression were observed in mice after administration of IMAB362. When administered intravenously in related animal species, no toxicity was observed in gastric tissues because the target epitope is inaccessible. However, the tumor target becomes accessible from IMAB362 during malignant transformation. IMAB362 provides four independent, very potent mechanisms of action: (i) antibody-dependent cytotoxicity (ADCC), (ii) complement-dependent cytotoxicity (CDC), (iii) induction of programmed cell death induced by cross-linking of the target at the tumor surface, and (iv) direct inhibition of diffusion.
[0006] In a previous Phase I clinical trial, IMAB362 was evaluated as a single dose for monotherapy in patients with late-stage gastroesophageal cancer. In this trial, five IMAB362 doses (33, 100, 300, 600, and 1000 mg / m²) were used. 2 ) was applied as monotherapy. Since this study did not show relevant differences between the treatment groups in AE profiles (AE = adverse effects) and other safety parameters with single administration of this antibody, 1000 mg / m² 2 It demonstrates that it is safe and well tolerated at doses up to 300 mg / m² 2 and 600 mg / m² 2 The group obtained the best results regarding antitumor activity. 300 mg / m² 2 In two patients of the group, the disease was controlled, and since they had only non-target lesions, they were evaluated as non-CR, non-PD (CD = Complete Response, PD = Progressive Disease). The duration of non-CR and non-PD was approximately 2 months and 6 weeks, respectively. Tumor marker levels remained stable in these three patients. 600 mg / m² 2 One patient in the group presented with a stable lesion (SD). The SD duration was approximately 2 months.
[0007] Based on the induced cytotoxicity of IMAB362, the survival benefit in IMAB362-treated mice with CLDN18.2-positive tumors, the absence of any indications of IMAB362-related toxicity, and the very potent mechanism of action for the promising results of the Phase I clinical trial, a Phase IIa study was initiated. This Phase IIa clinical trial was conducted to determine the safety, tolerability, and antitumor activity of repeated doses of IMAB362 in patients with metastatic, refractory, or relapsed disease of advanced adenocarcinoma of the stomach or lower esophagus, as evidenced by histology.
[0008] In this Phase IIa clinical trial, the investigational drug was administered to three sequentially mobilized cohorts. The first cohort of three patients received a low dose level (300 mg / m²). 2 Repeated doses of IMAB362 were administered based on body surface area. The antibody was administered via intravenous infusion over 2 hours. Since no signs of IMAB362-related toxicity were detected in the first cohort, the IMAB362 dose for the second cohort (3 patients) was 600 mg / m². 2 It increased with body surface area. In the 3rd cohort, 19 patients were assigned to the same dose (600 mg / m² 2 Repeated administration of body surface area). Patient samples from this cohort were analyzed for several companion analyses, namely ADCC, CDC, immunophenotype, and genetic immune polymorphism. All patients in all cohorts were administered repeated doses of IMAB362 every two weeks at the 2nd, 5th, 6th, 7th, and 8th visits (5 administrations).
[0009] The discrepancy in antigen-positive tumors (those that overexpress the target antigen to a similar degree) regarding responsiveness to interventions with therapeutic monoclonal antibodies such as IMAB362 suggests that there are additional factors related to treatment outcomes. This requires careful selection of patients who may benefit from antibody therapy.
[0010] Therefore, there is a need to develop tests to measure a patient's suitability for antibody therapy. The present invention addresses this need by providing markers associated with desirable or undesirable outcomes in antibody therapy. Furthermore, the present invention demonstrates that these markers are useful as indicators for prognosing clinical outcomes in cancer patients.
[0011] The findings presented herein can be used to select appropriate treatments for cancer patients, and in particular, to determine whether antibody therapy should be administered to cancer patients.
[0012] The present invention provides a method for analyzing single-nucleotide polymorphisms (SNPs) for use in evaluating the potential of an individual to respond to therapeutic treatment for cancer when selecting a treatment or prophylactic therapy (e.g., when deciding whether or not to administer a specific therapeutic agent to an individual with cancer or when determining who is at high risk of developing cancer in the future), or for evaluating an individual's prognosis regarding disease severity and recovery.
[0013] The present invention is based on the finding that specific genotypes for SNPs are associated with the susceptibility / insensitivity of cancer to antibody therapy, such as the treatment of CLDN18.2-positive cancer, particularly CLDN18.2-positive gastroesophageal cancer with IMAB362. The present invention is also based on the finding that specific genotypes for SNPs are associated with clinical outcomes in cancer patients and are useful for prognosing cancer.
[0014] In one aspect, the present invention is an evaluation method,
[0015] (i) If a cancer patient with a tumor antigen-positive tumor is a responder to antibody therapy against the tumor antigen, and / or
[0016] (ii) When a cancer patient, preferably a cancer patient with a tumor antigen-positive tumor, experiences progression-free survival,
[0017] The above method relates to an evaluation method comprising determining the genotype of one or more single-nucleotide polymorphisms selected from the group consisting of FCGR2A rs1801274, MUC1 rs4072037, IL-10 rs1800896, DNMT3A rs1550117, SMAD4 rs12456284, EGF rs4444903, CDH1 rs16260, ERCC1 rs11615, and FCGR3A rs396991 in a sample obtained from a patient.
[0018] In one embodiment, the presence of the heterozygous FCGR2A rs1801274 [CT] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0019] In one embodiment, the presence of the homozygous FCGR2A rs1801274 [TT] genotype and / or the homozygous FCGR2A rs1801274 [CC] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0020] In one embodiment, the presence of the homozygous MUC1 rs4072037 [AA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0021] In one embodiment, the presence of the homozygous MUC1 rs4072037 [GG] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0022] In one embodiment, the presence of the homozygous IL-10 rs1800896 [GG] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0023] In one embodiment, the presence of the heterozygous DNMT3A rs1550117 [GA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0024] In one embodiment, the presence of the heterozygous SMAD4 rs12456284 [GA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0025] In one embodiment, the homozygous EGF rs4444903 [AA] genotype represents a reduced risk in cancer patients who are not responders to antibody therapy and / or a reduced risk in cancer patients who have not experienced progression-free survival.
[0026] In one embodiment, the presence of a homozygous CDH1 rs16260 [AA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0027] In one embodiment, the presence of a homozygous ERCC1 rs11615 [TT] genotype indicates a reduced risk in cancer patients who are not responders to antibody therapy and / or a reduced risk in cancer patients who have not experienced progression-free survival.
[0028] In one embodiment, the presence of the heterozygous FCGR3A rs396991 [TG] genotype and / or the homozygous FCGR3A rs396991 [TT] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0029] In one embodiment, the presence of the homozygous FCGR3A rs396991 [GG] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0030] In one embodiment, the tumor antigen is the CLDN18.2 protein.
[0031] In one aspect, the present invention is an evaluation method,
[0032] (i) If a cancer patient with a CLDN18.2-positive tumor is a responder to antibody therapy against the CLDN18.2 protein, and / or
[0033] (ii) When a cancer patient, preferably a cancer patient with a CLDN18.2-positive tumor, experiences progression-free survival,
[0034] The above method relates to an evaluation method comprising determining the genotype of one or more single-nucleotide polymorphisms selected from the group consisting of FCGR2A rs1801274, MUC1 rs4072037, IL-10 rs1800896, DNMT3A rs1550117, SMAD4 rs12456284, EGF rs4444903, CDH1 rs16260, ERCC1 rs11615, and FCGR3A rs396991 in a sample obtained from a patient.
[0035] In one embodiment, the presence of the heterozygous FCGR2A rs1801274 [CT] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0036] In one embodiment, the presence of the homozygous FCGR2A rs1801274 [TT] genotype and / or the homozygous FCGR2A rs1801274 [CC] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0037] In one embodiment, the presence of the homozygous MUC1 rs4072037 [AA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0038] In one embodiment, the presence of the homozygous MUC1 rs4072037 [GG] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0039] In one embodiment, the presence of the homozygous IL-10 rs1800896 [GG] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0040] In one embodiment, the presence of the heterozygous DNMT3A rs1550117 [GA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0041] In one embodiment, the presence of the heterozygous SMAD4 rs12456284 [GA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0042] In one embodiment, the presence of the homozygous EGF rs4444903 [AA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0043] In one embodiment, the presence of a homozygous CDH1 rs16260 [AA] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0044] In one embodiment, the presence of a homozygous ERCC1 rs11615 [TT] genotype indicates a reduced risk in cancer patients who are not responders to antibody therapy and / or a reduced risk in cancer patients who have not experienced progression-free survival.
[0045] In one embodiment, the presence of the heterozygous FCGR3A rs396991 [TG] genotype and / or the homozygous FCGR3A rs396991 [TT] genotype indicates reduced risk in cancer patients who are not responders to antibody therapy and / or reduced risk in cancer patients who have not experienced progression-free survival.
[0046] In one embodiment, the presence of the homozygous FCGR3A rs396991 [GG] genotype indicates an increased risk in cancer patients who are not responders to antibody therapy and / or an increased risk in cancer patients who have not experienced progression-free survival.
[0047] In one embodiment of all aspects of the present invention, the antibody acts by mobilizing the patient's immune system to destroy tumor cells. In one embodiment, the antibody acts through antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC). In one embodiment, the antibody is a monoclonal antibody. In one embodiment of all aspects of the present invention, the antibody comprises a heavy chain comprising an amino acid sequence represented by SEQ ID NO. 17 or 51 or a fragment thereof and a light chain comprising an amino acid sequence represented by SEQ ID NO. 24 or a fragment thereof.
[0048] In one embodiment of all aspects of the present invention, non-responsiveness to antibody treatment includes a relative reduction in one or more of survival, progression-free survival, relapse-free survival, distant relapse-free survival, and stable disease.
[0049] In one aspect, the present invention is a method for treating cancer patients,
[0050] a. A step of evaluating whether a cancer patient is a responder to antibody therapy by the method of the present invention, and
[0051] b. (i) a step of treating a cancer patient with an antibody when the patient has reduced risk because the patient is not a responder to antibody therapy, or (ii) a step of not treating the cancer patient with an antibody including a treatment different from antibody therapy when the patient has increased risk because the patient is not a responder to antibody therapy, and / or a step of treating the cancer patient with a therapeutic regimen.
[0052] In one embodiment, the therapeutic regimen includes treatment that is not dependent on the patient's immune system. In one embodiment, the therapeutic regimen does not include treatment with antibodies that act by mobilizing the patient's immune system to destroy tumor cells. In one embodiment, the therapeutic regimen includes surgery, chemotherapy, and / or radiation. In one embodiment, the therapeutic regimen includes treatment with small molecule inhibitors of tumor antigens and / or antibody-drug conjugates, wherein the antibody is against the tumor antigen. In one embodiment, the antibody-drug conjugate is an antibody bound to a radioactive, chemotherapy, or toxin portion. In one embodiment, the antibody-drug conjugate is an antibody bound to a cell proliferation-inhibiting or cytotoxic compound.
[0053] In one aspect, the present invention relates to a method for evaluating clinical outcomes of a cancer patient, the method comprising determining a genotype for one or more single-nucleotide polymorphisms selected from the group consisting of FCGR2A rs1801274, MUC1 rs4072037, IL-10 rs1800896, DNMT3A rs1550117, SMAD4 rs12456284, EGF rs4444903, CDH1 rs16260, ERCC1 rs11615, and FCGR3A rs396991 in a sample obtained from a patient.
[0054] In one embodiment, the presence of the heterozygous FCGR2A rs1801274 [CT] genotype indicates a reduced risk of poor clinical outcomes.
[0055] In one embodiment, the presence of the homozygous FCGR2A rs1801274 [TT] genotype and / or the homozygous FCGR2A rs1801274 [CC] genotype indicates an increased risk of poor clinical outcomes.
[0056] In one embodiment, the presence of the homozygous MUC1 rs4072037 [AA] genotype indicates a reduced risk of poor clinical outcomes.
[0057] In one embodiment, the presence of the homozygous MUC1 rs4072037 [GG] genotype indicates an increased risk of poor clinical outcomes.
[0058] In one embodiment, the presence of the homozygous IL-10 rs1800896 [GG] genotype indicates a reduced risk of poor clinical outcomes.
[0059] In one embodiment, the presence of the heterozygous DNMT3A rs1550117 [GA] genotype indicates a reduced risk of poor clinical outcomes.
[0060] In one embodiment, the presence of the heterozygous SMAD4 rs12456284 [GA] genotype indicates a reduced risk of poor clinical outcomes.
[0061] In one embodiment, the presence of the homozygous EGF rs4444903 [AA] genotype indicates a reduced risk of poor clinical outcomes.
[0062] In one embodiment, the presence of the homozygous CDH1 rs16260 [AA] genotype indicates a reduced risk of poor clinical outcomes.
[0063] In one embodiment, the presence of the homozygous ERCC1 rs11615 [TT] genotype indicates a reduced risk of poor clinical outcomes.
[0064] In one embodiment, the presence of the heterozygous FCGR3A rs396991 [TG] genotype and / or the homozygous FCGR3A rs396991 [TT] genotype indicates a reduced risk of poor clinical outcomes.
[0065] In one embodiment, the presence of the homozygous FCGR3A rs396991 [GG] genotype indicates an increased risk of poor clinical outcomes.
[0066] In one embodiment, evaluating the clinical outcome of a cancer patient includes predicting the likelihood of one or more of survival, progression-free survival, recurrence-free survival, distant recurrence-free survival, and a safe lesion. In one embodiment, a poor clinical outcome includes a relative decline in one or more of survival, progression-free survival, recurrence-free survival, distant recurrence-free survival, and a safe lesion.
[0067] In one embodiment, the patient has a tumor antigen-positive tumor and is treated with an antibody against the tumor antigen.
[0068] In one embodiment of all aspects of the present invention, the sample is a sample containing DNA. In one embodiment, the DNA is extracted from a patient's body sample. In one embodiment, the DNA is extracted from blood.
[0069] In one embodiment of all aspects of the present invention, the tumor is a solid tumor. In one embodiment, the tumor is a gastroesophageal tumor. In one embodiment, the tumor is an advanced adenocarcinoma of the stomach or lower esophagus. In one embodiment, the cancer is gastroesophageal cancer. In one embodiment, the cancer is an advanced adenocarcinoma of the stomach or lower esophagus.
[0070] In a further aspect, the present invention relates to a kit comprising means for determining the genotype of one or more single-nucleotide polymorphisms selected from the group consisting of FCGR2A rs1801274, MUC1 rs4072037, IL-10 rs1800896, DNMT3A rs1550117, SMAD4 rs12456284, EGF rs4444903, CDH1 rs16260, ERCC1 rs11615, and FCGR3A rs396991 in a sample obtained from a patient. In one embodiment, the kit is useful for carrying out the methods of all aspects of the present invention. In one embodiment, the kit further comprises a data carrier. In a preferred embodiment, the data carrier is an electronic or non-electronic data carrier. In one embodiment, the data carrier comprises instructions regarding a method for carrying out the methods of all aspects of the present invention.
[0071] Other objects, advantages, and features of the present invention will become apparent from the following detailed description when considered in conjunction with the accompanying drawings. Brief explanation of the drawing
[0072] Figure 1 shows single nucleotide polymorphisms with statistically significant changes in genotype frequency between the patient and control groups (χ² 2 -Test, p<0.05). The bars indicate the placement of SNP-specific genotypes. Pat. Patient group, Co. Control group. Figure 2 shows the relative frequency of homozygous risk genotypes per patient relative to the number of SNP risk factors investigated per patient. Patients are classified as the frequency of accumulated homozygous risk factors increases. Figure 3 shows progression-free survival of PP patients differentiated by the rs1801274 (FCGR2A) genotype (Kaplan-Meier curve). Figure 4 shows progression-free survival of FAS patients differentiated by the rs1801274 (FCGR2A) genotype (Kaplan-Meier curve). Figure 5 shows progression-free survival of PP patients differentiated by the rs1800896 (IL-10) genotype (Kaplan-Meier curve). Figure 6 shows progression-free survival of FAS patients differentiated by the rs1800896 (IL-10) genotype (Kaplan-Meier curve). Figure 7 shows progression-free survival of FAS patients differentiated by the rs1550117 (DNMT3A) genotype (Kaplan-Meier curve). Figure 8 shows progression-free survival of PP patients differentiated by the rs12456284 (SMAD4) genotype (Kaplan-Meier curve). Figure 9 shows progression-free survival of PP patients differentiated by the rs4072037 (MUC1) genotype (Kaplan-Meier curve). Figure 10 shows progression-free survival of FAS patients differentiated by the rs4072037 (MUC1) genotype (Kaplan-Meier curve). Figure 11 shows progression-free survival of FAS patients differentiated by the rs4444903 (EGF) genotype (Kaplan-Meier curve). Figure 12 shows progression-free survival of FAS patients differentiated by the rs16260 (CDH1) genotype (Kaplan-Meier curve). Figure 13 shows progression-free survival of PP patients differentiated by the rs11615 (ERCC1) genotype (Kaplan-Meier curve). Figure 14 shows progression-free survival of PP patients differentiated by the rs396991 (FCGR3A) genotype (Kaplan-Meier curve). Specific details for implementing the invention
[0073] Although the present invention is described in more detail below, it should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described herein, as methodologies, protocols, and reagents vary widely. Furthermore, the terms used herein are intended only to describe specific embodiments and should not be interpreted as being intended to limit the scope of the invention, and the scope of the invention should be understood to be limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.
[0074] The components of the present invention are described below. While these components are listed with specific embodiments, it should be understood that they may be combined in any manner and any number to provide additional embodiments. The various described embodiments and preferred embodiments should not be interpreted as limiting the invention to the explicitly described embodiments alone. This specification should be understood to support and encompass embodiments that combine the explicitly described embodiments with any number of disclosed and / or preferred components. Furthermore, any permutations and combinations of all described members of this application should be deemed to be disclosed by the description of this application unless otherwise indicated by the context.
[0075] Preferably, the terms used herein are defined as described in the document “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", HGW Leuenberger, B. Nagel, and H. Koelbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).
[0076] Unless otherwise specified, the practice of the present invention will employ conventional chemical, biochemical, cellular biological, and immunological methods and recombinant DNA technology as described in the literature of the art (e.g., for reference, Molecular Cloning: A Laboratory Manual , 2 nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
[0077] Throughout this specification and the following claims, unless the context otherwise requires, variations such as the words “comprising,” “comprising,” and “comprising” are to be understood to mean that they include the specified members, integers, or steps, or groups of members, integers, or steps, even though some embodiments may exclude such other members, integers, or steps, or groups of members, integers, or steps; that is, the subject matter of the claims of the invention includes the specified members, integers, or steps, or groups of members, integers, or steps. The terms “one,” “one (indefinite article),” “definite article,” and similar reference terms used in the context describing the invention (particularly in the context of the claims) may be interpreted to include both singular and plural forms unless otherwise specified herein or clearly negated by the context. The reference of values of the invention to ranges is merely for the purpose of easily and individually designating each distinct value belonging to such ranges. Unless otherwise specified herein, each individual value is deemed to be incorporated into this specification as individually referred to herein. All methods described herein may be performed in any appropriate order unless otherwise specified herein or clearly negated by the context. Any and all examples or illustrative language provided herein (e.g., “e.g.,”) are intended merely to better illuminate the invention and do not otherwise add limitations to the scope of the claimed invention. No language in this specification should be interpreted as referring to any unclaimed component essential to the practice of the invention.
[0078] Several documents are cited throughout the body of this specification. Each of the above or below documents cited herein (all patents, patent applications, scientific publications, manufacturers' manuals, instructions, etc.) is incorporated herein by reference in its entirety, whether more or less. It should not be construed that the present invention does not precede such disclosures on the grounds that these documents are prior art.
[0079] The inventors provide a test method for measuring a patient's suitability for a specific cancer treatment, particularly antibody therapy, and for estimating the prognosis of a cancer patient. Based on the results obtained using these tests, a physician can determine an appropriate treatment for a cancer patient, and in particular, determine whether antibody therapy should be administered to a specific cancer patient.
[0080] The term "single nucleotide polymorphism" or "SNP" relates to DNA sequence variations in which a single nucleotide occurs commonly within the genome (or other shared sequences) across different populations, either among members of a biological species or between paired chromosomes. SNPs can occur in the coding sequence of a gene, the non-coding region of a gene, or the intergene region (the region between genes). Due to the degeneration of the genetic code, SNPs within the coding sequence may not necessarily alter the amino acid sequence of the resulting protein. Therefore, SNPs in the coding region are classified into two types: synonymous SNPs and non-synonymous SNPs. Synonymous SNPs do not affect the protein sequence, whereas non-synonymous SNPs alter the amino acid sequence of the protein. Non-synonymous SNPs include two types: missense and nonsense. SNPs not located in the protein-coding region can nevertheless affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of non-coding RNA. Gene expression affected by this type of SNP is called an eSNP (expression SNP), and it can be located upstream or downstream of the gene.
[0081] Various methods known in the art can be used to determine the genotype for an SNP. Analytical methods for discovering novel SNPs and detecting known SNPs include, for example, DNA sequencing, capillary electrophoresis, mass spectrometry, single-stranded polymorphism (SSCP), electrochemical analysis, denaturation HPLC and gel electrophoresis, restriction enzyme fragment length polymorphism (RFLP), and hybridization analysis.
[0082] For any one or two alleles, the process of determining the nucleotides present at a specific SNP location described herein may be referred to by phrases such as “determining the genotype for the SNP” or “SNP genotype analysis.” Accordingly, these phrases may refer to detecting a single allele (nucleotide) at the SNP location or may include detecting all alleles (nucleotides) at the SNP location (as in determining the homozygous or heterozygous state of the SNP location). Additionally, these phrases may refer to detecting amino acid residues encoded by the SNP (such as alternative amino acid residues encoded by different codons generated by alternative nucleotides at the SNP location).
[0083] A reagent that specifically detects a specific target SNP location described herein, preferably specific to a specific nucleotide (allele) at the target SNP location (i.e., the reagent preferably allows for the identity of the nucleotide present at the target SNP location to be determined, since it can distinguish between different alternative nucleotides at the target SNP location) may be used for SNP detection. Typically, such a detection reagent hybridizes to a target SNP-containing nucleic acid molecule by complementary base pairing in a sequence-specific manner and distinguishes the target variant sequence from other nucleic acid sequences, as in forms known in the art in a test sample. Examples of detection reagents are non-naturally occurring nucleic acid primers or probes that hybridize to the target nucleic acid containing the SNP disclosed herein. In a preferred embodiment, such primers or probes can distinguish a nucleic acid having a specific nucleotide (allele) at the target SNP location from other nucleic acids having different nucleotides at the same target SNP location. Additionally, the detection reagent may hybridize to a specific region 5' and / or 3' of the SNP location. It will be apparent to those skilled in the art that detection reagents, such as these primers and probes, are directly useful as reagents for genetic analysis of one or more of the SNPs disclosed herein and can be incorporated in any kit form.
[0084] To analyze SNPs, it may be appropriate to use oligonucleotides specific to alternative SNP alleles. These oligonucleotides that detect single nucleotide variations in target sequences may be referred to by terms such as "allele-specific oligonucleotides," "allele-specific probes," or "allele-specific primers."
[0085] SNP detection reagents may be labeled with a reporter, such as a fluorescent reporter dye, that emits a detectable signal. A preferred reporter dye is a fluorescent dye, but any reporter dye that can be attached to a detection reagent, such as an oligonucleotide probe or primer, is suitable for the present invention. In another embodiment, particularly when the reagent is used as a self-quenching probe such as a TaqMan probe, the detection reagent may be additionally labeled with a quencher dye. The SNP detection reagents disclosed herein include other labels and include, but are not limited to, biotin for streptavidin binding, heptin for antibody binding, and oligonucleotides for binding to other complementary oligonucleotides.
[0086] Additionally, according to the present invention, reagents used to test one or more SNPs disclosed herein are also considered, even though they do not contain (or are not complementary to) the SNP nucleotide to be identified. For example, a primer that is positioned adjacently but does not hybridize directly to the target SNP site is useful for a primer extension reaction in which the primer hybridizes to a region adjacent to the target SNP site (i.e., within one or more nucleotides of the target SNP site). During the primer extension reaction, if a specific nucleotide (allele) is present at the target SNP site, the primer typically cannot extend past the target SNP site, and the primer extension product can be detected to determine which SNP allele is present at the target SNP site. For example, a specific ddNTP is typically used in a primer extension reaction in which the primer extension is terminated when the ddNTP is incorporated into the extension product. Thus, reagents that bind to a nucleic acid molecule in a region adjacent to the SNP site and reagents used to test the SNP site are also considered according to the present invention, even if the bound sequence does not necessarily contain the SNP site itself.
[0087] The term "FCGR2A" refers to the human FCGR2A gene. This gene encodes the low-affinity immunoglobulin gamma Fc region receptor II-a (CD32) and is a member of the immunoglobulin Fc receptor gene family. The protein encoded by this gene is a cell surface receptor found in phagocytic cells such as macrophages and neutrophils, and is involved in phagocytosis and the removal of immune complexes. Selective splicing results in various transcriptional variants.
[0088] Preferably, the term "FCGR2A" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 61 of the sequence list or a variant of said nucleic acid sequence, preferably a protein encoded by said nucleic acid, preferably a protein encoded by said nucleic acid, and preferably a protein comprising the amino acid sequence of SEQ ID NO. 62 of the sequence list or a variant of said amino acid sequence.
[0089] rs1801274 is an SNP of the FCGR2A gene. rs1801274 (C) encodes the arginine (R) allele along with the (T) allele encoding the mutant histidine (H). This SNP is an intragenetic transition substitution with the following codon changes, CAT and CGT, and causes missense mutations. The SNP is known in the literature by many names, including A519C and R131H. The context sequence is as follows:
[0090] TGGGATGGAGAAGGTGGGATCCAAA[C / T]GGGAGAATTTCTGGGATTTTCCATT
[0091] The term "MUC1" refers to the human MUC1 gene. This gene is a membrane-bound, glycosylated phosphoprotein that encodes Mucin 1, Cell Surface Associated (MUC1), or Polymorphic Epithelial Mucin (PEM), a member of the mucin family. The protein is anchored to the anterior surface of many epithelium by its transmembrane domain. Beyond the transmembrane domain is the SEA domain, which contains a cleavage site for the release of the large extracellular domain. This protein performs a protective function by binding to pathogens and also exerts cellular signaling capabilities.
[0092] Preferably, the term "MUC1" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 63 of the sequence list or a variant of said nucleic acid sequence, preferably a protein encoded by said nucleic acid, and preferably a protein comprising the amino acid sequence of SEQ ID NO. 64 of the sequence list or a variant of said amino acid sequence.
[0093] rs4072037 is an SNP of the MUC1 gene. This SNP is an intrageneic transfer substitution with the following codon changes, ACA and ACG, and causes a silent mutation. The context sequence is as follows:
[0094] CCCCTAAACCCGCAACAGTTGTTAC[A / G]GGTTCTGGTCATGCAAGCTCTACCC
[0095] The term "IL-10" refers to the human IL-10 gene. This gene encodes interleukin-10 (IL-10), also known as the cytokine synthesis inhibitor (CSIF), an anti-inflammatory cytokine.
[0096] Preferably, the term "IL-10" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 65 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 66 of the sequence list or a variant of said amino acid sequence.
[0097] rs1800896 is an SNP of the IL-10 gene. This SNP is an intergene / unknown intrageneic transfer substitution. The context sequence is as follows:
[0098] CAACACTACTAAGGCTTCTTGGGA[A / G]GGGGAAGTAGGGATAGGTAAGAGGA
[0099] The term "DNMT3A" refers to the human DNMT3A gene. This gene encodes DNA(cytosine-5)-methyltransferase 3A. The protein encoded by this gene is an enzyme that catalyzes the transfer of methyl groups from DNA to specific CpG structures.
[0100] Preferably, the term "DNMT3A" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 67 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 68 of the sequence list or a variant of said amino acid sequence.
[0101] rs1550117 is an SNP in the DNMT3A gene. This SNP is an intragenetic transfer substitution in the DNMT3A promoter region. The context sequence is as follows:
[0102] AATTCCACCAGCACAGCCACTCACT[A / G]TGTGCTCATCTCACTCCTCCAGCAG
[0103] The term "SMAD4" refers to the human SMAD4 gene. This gene encodes the parent gene for decapentaplegic homolog 4. The protein encoded by this gene belongs to the Darfwin protein family, which is involved in cell signaling and regulates members of the TGFβ protein superfamily. It binds to receptor-regulated SMADs such as SMAD1 and SMAD2, forming a complex that binds to DNA and acts as a transcription factor. This is the only known mammalian coSMAD.
[0104] Preferably, the term "SMAD4" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 69 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 70 of the sequence list or a variant of said amino acid sequence.
[0105] rs12456284 is an SNP of the SMAD4 gene. This SNP is an intragenetic transfer substitution in the 3'-UTR. The context sequence is as follows:
[0106] AGGTCCAGAGCCAGTGTTCTTGTTC[A / G]ACCTGAAAGTAATGGCTCTGGGTTG
[0107] The term "EGF" refers to the human EGF gene. This gene encodes epidermal growth factor. EGF is a growth factor that promotes cell growth, proliferation, and differentiation by binding to the receptor EGFR.
[0108] Preferably, the term "EGF" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 71 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 72 of the sequence list or a variant of said amino acid sequence.
[0109] rs4444903 is an SNP of the EGF gene. This SNP is an intragenetic transfer substitution in the 5'-UTR. The context sequence is as follows:
[0110] CTTTCAGCCCCAATCCAAGGGTTGT[A / G]GCTGGAACTTTCCATCAGTTCTTCC
[0111] The term "CDH1" refers to the human CDH1 gene. This gene encodes cadherin-1, also known as CAM 120 / 80, epithelial cadherin (E-cadherin), or uvomorulin. This protein is a typical member of the cadherin superfamily. It is a calcium-dependent cell-cell adhesion glycoprotein composed of five extracellular cadherin repeats, a transmembrane region, and a highly conserved cytoplasmic tail. Loss of function is thought to contribute to the progression of cancer by increasing proliferation, invasion, and / or metastasis.
[0112] Preferably, the term "CDH1" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 73 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 74 of the sequence list or a variant of said amino acid sequence.
[0113] rs16260 is an SNP in the CDH1 gene. This SNP is an intrageneic transversion substitution located in the promoter region of the CDH1 gene. The context sequence is as follows:
[0114] CTAGCAACTCCAGGCTAGAGGGTCA[A / C]CGCGTCTATGCGAGGCCGGGTGGGC
[0115] The term "ERCC1" refers to the human ERCC1 gene. This gene encodes the DNA break repair protein ERCC-1. The primary function of the ERCC1 protein is to repair nucleotide breaks in damaged DNA.
[0116] Preferably, the term "ERCC1" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 75 of the sequence list or a variant of said nucleic acid sequence, and to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 76 of the sequence list or a variant of said amino acid sequence.
[0117] rs11615 is an SNP in the ERCC1 gene. This SNP is a silent intragenetic transfer substitution. The context sequence is as follows:
[0118] ATCCCGTACTGAAGTTCGTGCGCAA[C / T]GTGCCCTGGGGAATTTGGCGACGTAA
[0119] The term "FCGR3A" refers to the human FCGR3A gene. This gene encodes the low-affinity immunoglobulin gamma Fc region receptor III-A. The protein encoded by this gene is part of a cluster of differentiated cell surface molecules.
[0120] Preferably, the term "FCGR3A" relates to a nucleic acid comprising the nucleic acid sequence of SEQ ID NO. 77 of the sequence list or a variant of said nucleic acid sequence, preferably to a protein encoded by said nucleic acid, and preferably to a protein comprising the amino acid sequence of SEQ ID NO. 78 of the sequence list or a variant of said amino acid sequence.
[0121] rs396991 is an SNP in the FCGR3A gene. This SNP is an intrageneic conversion substitution with the following codon changes, GTT and TTT, and causes a missense mutation. rs396991 (T) encodes the phenylalanine (F) allele, and the (G) allele encodes the mutated valine (V). The context sequence is as follows:
[0122] CGGCTCCTACTTCTGCAGGGGGCTT[G / T]TTGGGAGTAAAAAATGTGTCTTCAGA
[0123] Claudins are a family of proteins that are the most important components of tight junctions, forming a paracellular barrier that controls molecular flow in the intercellular space between epithelial cells. Claudins are transmembrane proteins that traverse the membrane four times, with both the N-terminus and C-terminus located in the cytoplasm. The first extracellular loop or domain consists of an average of 53 amino acids, and the second extracellular loop or domain consists of approximately 24 amino acids. Among the claudin family, cell surface proteins, such as CLDN18.2, are expressed in tumors of various origins and are particularly suitable as target constructs in relation to antibody-mediated cancer immunotherapy due to their selective expression (no expression in toxicity-related normal tissues) and localization to the plasma membrane.
[0124] As used herein, the term "CLDN" means claudin and includes CLDN18.2. Preferably, the claudin is human claudin.
[0125] The term "CLDN18" relates to Claudin 18 and includes all variants including Claudin 18 splice variant 1 (Claudin 18.1 (CLDN18.1)) and Claudin 18 splice variant 2 (Claudin 18.2 (clDN18.2)).
[0126] The term "CLDN18.2" preferably relates to human CLDN18.2, and in particular to a protein comprising an amino acid sequence according to SEQ ID NO. 1 of the sequence listing or a variant of said amino acid. The first extracellular loop or domain of CLDN18.2 preferably comprises 27 to 81 amino acids of the amino acid sequence shown in SEQ ID NO. 1, more preferably 29 to 78 amino acids. The second extracellular loop or domain of CLDN18.2 preferably comprises 140 to 180 amino acids of the amino acid sequence shown in SEQ ID NO. 1. The first and second extracellular loops or domains preferably form the extracellular portion of CLDN18.2.
[0127] CLDN18.2 is selectively expressed in differentiated epithelial cells of the gastric mucosa in normal tissues. CLDN18.2 is expressed in cancers of various origin, such as pancreatic carcinoma, esophageal carcinoma, gastric carcinoma, bronchial carcinoma, breast carcinoma, and ENT tumors. CLDN18.2 is an important target for the prevention and / or treatment of primary tumors, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer (such as non-small cell lung cancer (NSCLC)), ovarian cancer, colorectal cancer, liver cancer, head and neck cancer, gallbladder cancer, and their metastases, particularly gastric cancer metastases such as Krukenberg's tumor, peritoneal metastasis, and lymph node metastasis.
[0128] The term "CLDN18.1" preferably relates to human CLDN18.1, and particularly preferably relates to a protein comprising an amino acid sequence according to SEQ ID NO. 2 of the SEQ List or a variant of said amino acid sequence.
[0129] As used herein, "prognosis" refers to the prediction of an outcome, specifically the probability of progression-free survival (PFS) or disease-free survival (DFS). Survival rates are generally calculated as the average number of months (or years) in which 50% of patients survive, or as the percentage of patients alive after 1, 5, 15, and 20 years. Prognosis is important in treatment decisions because patients with a good prognosis are generally provided with less invasive treatments, while patients with a poor prognosis are generally provided with more aggressive treatments, such as broader chemotherapy drugs.
[0130] As used herein, "prediction" refers to providing information regarding possible responses of a disease to a separate therapeutic treatment.
[0131] The phrase "indicates risk" refers to a specific degree of possibility or probability. The phrase "indicates reduced risk" refers to a low degree of possibility or probability. The phrase "indicates increased risk" refers to a specific degree, higher, or greater degree of possibility or probability.
[0132] In the case where the case "represents a reduced risk in a cancer patient who is not a responder to antibody therapy," the above case indicates that the cancer patient is a responder to antibody therapy; that is, there is a possibility that the patient is a responder to antibody therapy, and selectively, the likelihood of the patient being a responder to antibody therapy is higher than the likelihood of the patient not being a responder to antibody therapy.
[0133] When a case "indicates an increased risk in cancer patients who are not responders to antibody therapy," the above case indicates that the cancer patient is not a responder to antibody therapy; that is, there is a possibility that the patient is not a responder to antibody therapy, and selectively, the likelihood that the patient is not a responder to antibody therapy is higher than the likelihood that the patient is a responder to antibody therapy.
[0134] When a case "indicates a reduced risk of a bad clinical outcome," the case indicates a good clinical outcome; that is, there is a possibility of a good clinical outcome, and selectively, the likelihood of a good clinical outcome is higher than the likelihood of a bad clinical outcome.
[0135] When a case "indicates an increased risk of a bad clinical outcome," the case indicates a bad clinical outcome; that is, there is a possibility of a bad clinical outcome, and the likelihood of a bad clinical outcome is higher than the likelihood of a good clinical outcome.
[0136] When a case "represents a reduced risk for cancer patients who have not experienced progression-free survival," the above case indicates that the cancer patient has experienced progression-free survival; that is, the patient has a possibility of experiencing progression-free survival, and selectively, the patient is more likely to experience progression-free survival than not to.
[0137] When a case "indicates an increased risk in cancer patients who have not experienced progression-free survival," the above case indicates that the cancer patient has not experienced progression-free survival; that is, there is a possibility that the patient will not experience progression-free survival, and the likelihood of the patient not experiencing progression-free survival is higher than the likelihood of the patient selectively experiencing progression-free survival.
[0138] As used herein, the term “sample” refers to any material obtained from a subject and which can be used for analytical purposes, particularly for determining the genotype for one or more single-nucleotide polymorphisms. In certain embodiments, the sample described herein may be, for example, any tissue, cell, and / or cell in a biological fluid from a mammal or human to be tested, or may be derived therefrom. The sample may be isolated from a patient, for example, a human body. The sample may be a fractionated and / or purified sample. For example, the sample included in the invention may be a tissue sample (e.g., a section or explant), a single cell sample, a cell colony sample, a cell culture sample, a blood sample (e.g., a blood fraction such as whole blood or blood cell fraction, serum or plasma), a urine sample, or a sample from other peripheral sources, or may be derived therefrom. In a particularly preferred embodiment, the sample is a tissue sample (e.g., a biopsy from a subject having or suspected of having cancerous tissue). For example, the sample may be a biopsy of a tumor. Samples may be obtained from the patient before the initiation of therapeutic treatment, during therapeutic treatment, and / or after therapeutic treatment, for example, before, during, or after the administration of cancer therapy.
[0139] Sample material may be used to produce nucleic acid extracts (including DNA and / or RNA), proteins, or membrane extracts from any body fluid (e.g., blood, serum, plasma, urine, saliva, sputum, gastric juice, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, oral epithelial cells (buccal swabs), or tissue or tumor specimens.
[0140] Furthermore, the present invention relates to a kit comprising means, such as a reagent, for determining the genotype of one or more single-nucleotide polymorphisms as described herein. In the context of the present invention, the term “part of the kit (simply put, kit”) is understood as any combination of at least some of the components identified herein, which may include those combined while spatially coexisting in a functional unit and additional components. For example, the kit may include a pre-selected primer or probe specific to a nucleic acid sequence containing one or more single-nucleotide polymorphisms to be genotyped. Additionally, the kit may include an enzyme suitable for nucleic acid amplification (e.g., a polymerase such as Taq), and deoxynucleotides and buffers required for the reaction mixture for amplification. Additionally, the kit may include a probe specific to one or more single-nucleotide polymorphisms. In certain embodiments, said means are detectably labeled.
[0141] The kit of the present invention may comprise (i) a container and / or (ii) a data carrier. The container may be filled with one or more of the means or reagents described above. The data carrier may be a non-electronic data carrier, such as a graphic data carrier like an information leaflet, information sheet, barcode, or access code, or an electronic data carrier, such as a floppy disk, compact disc (CD), digital multi-purpose disc (DVD), microchip, or other semiconductor-based electronic data carrier. The access code enables access to a database, such as an internet database, a centralized database, or a distributed database. The data carrier may include instructions that enable the analysis of results obtained with the kit, and instructions for the use of the kit in particular in the method of the present invention.
[0142] Additionally or alternatively, the kit may include materials desirable from a commercial and user perspective, including buffers, reagents, and / or diluents.
[0143] Based on the results obtained (i.e., based on the genotype for one or more single-nucleotide polymorphisms), the physician may select a cancer treatment regimen, particularly antibody therapy, to which the patient is predicted to respond. Preferably, a cancer treatment regimen to which the patient is predicted not to respond is not administered to the patient.
[0144] Based on the predicted outcome that the patient will not respond to antibody therapy, particularly antibody therapy that works by mobilizing the patient's immune system to destroy tumor cells, a physician may choose to administer a cancer treatment different from antibody therapy, particularly antibody therapy that works by mobilizing the patient's immune system to destroy tumor cells. In particular, the physician may choose to administer chemotherapy.
[0145] Based on the predicted outcome that the patient will respond to antibody therapy, particularly antibody therapy that works by mobilizing the patient's immune system to destroy tumor cells, the physician may choose to administer antibody therapy, particularly antibody therapy that works by mobilizing the patient's immune system to destroy tumor cells, and may optionally choose to administer it in combination with chemotherapy.
[0146] The term “(therapeutic) treatment” relates to any treatment aimed at improving the patient’s health condition and / or extending (increasing) the patient’s lifespan, particularly in relation to the treatment of cancer as used herein. Such treatment may eliminate cancer, reduce the size or number of tumors in the patient, prevent or reduce the development of cancer in the patient, inhibit or reduce the development of new cancer in the patient, reduce the frequency or severity of symptoms in the patient and / or reduce recurrence in patients who currently have cancer or have previously had cancer. Such treatment of cancer may be selected from the group consisting of surgery, chemotherapy, radiation therapy, and targeted therapy. One particularly preferred treatment according to the present invention is a treatment of cancer comprising a therapeutic monoclonal antibody against a tumor antigen, such as CLDN18.2, expressed on target cells.
[0147] Adjuvant therapy is administered in addition to primary, main, or initial treatment. Surgical procedures and combination therapies used in cancer treatment have become terms primarily used to describe adjuvant cancer therapy. An example of adjuvant therapy is an additional treatment typically administered after surgery when all detectable disease has been eliminated but a statistical risk of recurrence still remains due to potential disease.
[0148] Terms such as “responsive” or “responder” refer to the fact that a patient has a therapeutic benefit from a given treatment regimen in a therapeutic setting, and specifically refer to the observation of disease remission, prevention, or elimination, including shortening the duration of the disease, inhibiting or reducing the progression or exacerbation of the disease, inhibiting or reducing the development of new disease and / or relapse, preventing or delaying the onset or symptoms of the disease, reducing the frequency or severity of symptoms in patients currently suffering from or who have previously suffered from the disease, and / or extending the patient's lifespan. In particular, these refer to the observation of a reduction in tumor volume or an increase in tumor-free time, relapse-free time, or overall survival time.
[0149] Terms such as "non-adapted" or "non-responder" refer to the fact that a patient does not respond to a given treatment method in a therapeutic setting, specifically describing a state where no remission, prevention, or elimination of the disease has been observed—in other words, the patient is resistant to treatment.
[0150] A complete response is defined as the absence of any residual disease, such as cancer, and is generally evaluated by pathological analysis of acquired tissue samples. In this context, the term "pathological complete response (pCR)" is frequently used. Specifically, pCR is defined as the absence of residual invasive tumor cells in the original tumor bed. However, the definition of pCR may vary depending on different grading systems. Pathological complete response has been shown not only as a prognostic factor for better survival but also for disease-free survival and recurrence-free survival.
[0151] Recurrence-free survival is defined as the first time from randomization to recurrence or relapse, and the second time to cancer or death.
[0152] Progression-free survival (PFS) is a type of survival rate that measures the length of time during and after medication or during and after treatment while the disease to be treated (typically cancer) does not worsen. It is used as a measure to assess the effectiveness of new treatments in studying the health of patients with the disease, and is often used as a clinical endpoint in randomized controlled trials for cancer treatment.
[0153] According to the present invention, the term “cancer patient who has experienced progression-free survival” relates to a cancer patient who has an extended period without progression of the disease, particularly when compared to the average of patients and / or to patients who are non-responders to a given treatment method. Preferably, the extended period is at least 4, preferably at least 5, more preferably at least 6 months, e.g., at least 7 months or at least 8 months, and the period begins, e.g., from the time of the first administration of treatment.
[0154] The term "clinical outcome" is defined as the clinical result of a disease, for example, the reduction or improvement of symptoms, particularly after treatment.
[0155] In the context of cancer, the term "recurrence" includes the development of tumor cells in the same site and organ of the primary disease, distant metastasis that may occur years after the initial diagnosis and treatment of cancer, or localized cases such as the infiltration of tumor cells into local lymph nodes.
[0156] The terms “individual” and “subject” are used interchangeably herein. They refer to a human, non-human primate, or other mammal (e.g., mouse, rat, rabbit, dog, cat, cattle, pig, sheep, horse, or primate) that is suffering from or vulnerable to a disease or disability (e.g., cancer), but may or may not have the disease or disability. In many embodiments, the individual is a human. Unless otherwise specified, the terms “individual” and “subject” do not denote a specific age and thus encompass adults, the elderly, children, and newborns. In a preferred embodiment of the invention, the “individual” or “subject” is a “patient.” The term “patient” means a subject of treatment according to the invention, particularly a subject with a disease.
[0157] In a particularly preferred embodiment, the method of the present invention is performed on a patient who has already been diagnosed with cancer.
[0158] "Target cell" may mean any undesirable cell, such as a cancer cell. In a preferred embodiment, the target cell expresses CLDN18.2.
[0159] In the context of the present invention, terms such as "protect," "prevent," or "preventive" relate to preventing the occurrence and / or spread of disease in a subject, and in particular, to minimizing the possibility of the subject developing a disease or delaying the development of the disease. For example, a patient at risk of developing cancer may be a candidate for a treatment to prevent cancer.
[0160] "At risk" refers to subjects identified as having a higher-than-normal probability of developing a disease, particularly cancer, compared to the general population. Additionally, subjects who have suffered from or are currently suffering from a disease, particularly cancer, are subjects with an increased risk of developing the disease; for example, subjects may continue to develop the disease. Subjects who currently have cancer or have had cancer have an increased risk of cancer metastasis.
[0161] As used herein, in relation to the administration of treatment, the term “combination” refers to the use of one or more therapeutic regimens or therapeutic agents. The use of the term “combination” does not limit the order in which therapeutic regimens or therapeutic agents are administered to a subject. A therapeutic regimen or therapeutic agent may be administered before, simultaneously with, or after a second therapeutic regimen or therapeutic agent is administered to the subject. Preferably, the therapeutic regimen or therapeutic agent is administered to the patient in an order, amount, and / or time interval in which the therapeutic regimen or therapeutic agent can act together. In certain embodiments, the therapeutic regimen or therapeutic agent is administered to the subject in an order, amount, and / or time interval that provides increased benefit than when otherwise administered, particularly when administered independently of each other. Preferably, the increased benefit is synergistic.
[0162] The term "disease" refers to an abnormal condition affecting an individual's body. Disease is often interpreted as a health condition associated with specific symptoms and signs. Disease can be caused by factors attributable to external causes, such as infectious diseases, or by internal dysfunctions, such as autoimmune diseases. In the case of humans, "disease" is used more broadly to refer to any condition that causes pain, dysfunction, suffering, social problems, or death to the suffering individual, or similar problems for those in contact with the individual. In a broader sense, it may be considered a category that is sometimes distinct for different contexts or purposes, but includes injuries, disabilities, symptoms of disability, syndromes, infections, isolated symptoms, abnormal behavior, and atypical alterations of structure and function. Disease usually affects an individual not only physically but also emotionally, and contracting and living with many diseases can alter one's views of life and personality. According to the present invention, the term "disease" includes cancer, specifically the forms of cancer described herein. Any reference to cancer or specific forms of cancer also includes its metastasis. In a preferred embodiment, the disease to be treated according to the present invention comprises cells expressing a tumor antigen such as CLDN18.2.
[0163] "Diseases comprising cells expressing tumor antigens" means that, according to the present invention, a tumor antigen such as CLDN18.2 is expressed in cells of a diseased tissue or organ. In one embodiment, the expression of the tumor antigen in cells of a diseased tissue or organ is increased compared to the state of a healthy tissue or organ. The increase refers to an increase of at least 10%, particularly at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, at least 1000%, or at least 10000% or more. In one embodiment, expression is found only in the diseased tissue, whereas expression in the corresponding healthy tissue is suppressed. According to the present invention, diseases comprising cells expressing tumor antigens include cancer diseases. Furthermore, according to the present invention, cancer diseases are preferably diseases in which cancer cells express tumor antigens.
[0164] The term "cancer disease" or "cancer" generally refers to or describes a physiological condition of an individual characterized by uncontrolled cell growth. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias. More specifically, examples of such cancers include bone cancer, blood cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, colon cancer, breast cancer, prostate cancer, uterine cancer, carcinoma of the genitals and reproductive organs, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, central nervous system (CNS) tumors, neuroectodermal cancers, vertebral axis tumors, gliomas, meningiomas, and pituitary adenomas. The term "cancer" according to the present invention also includes cancer metastasis. Preferably, the “cancer disease” is characterized by cells expressing a tumor antigen such as CLDN18.2, and the cancer cells express such a tumor antigen. Cells expressing a tumor antigen such as CLDN18.2 are preferably cancer cells of the cancer described herein.
[0165] According to the present invention, the terms “tumor” or “tumor disease” preferably refer to abnormally growing cells (referred to as neoplastic cells, tumorigenous cells, or tumor cells) that form a swelling or lesion. “Tumor cells” means abnormal cells that grow by rapid and uncontrolled cell proliferation and continue to grow even after the stimulus that initiated new growth has ceased. A tumor forms a distinct mass of tissue that is partially or completely lacking in structural organization and functional coordination with normal tissue and may generally be benign, pre-malignant, or malignant.
[0166] In one embodiment, the cancer according to the present invention comprises cancer cells expressing a tumor antigen such as CLDN18.2. In one embodiment, the cancer is positive for a tumor antigen such as CLDN18.2. In one embodiment, the expression of a tumor antigen such as CLDN18.2 occurs on the cell surface. In one embodiment, at least 50%, preferably 60%, 70%, 80%, or 90% of the cancer cells are positive for a tumor antigen such as CLDN18.2 and / or at least 40%, preferably at least 50%, of the cancer cells are positive for surface expression of a tumor antigen such as CLDN18.2. In one embodiment, at least 95% or at least 98% of the cancer cells are positive for a tumor antigen such as CLDN18.2. In one embodiment, at least 60%, at least 70%, at least 80%, or at least 90% of the cancer cells are positive for surface expression of a tumor antigen such as CLDN18.2.
[0167] In one embodiment, the cancer or CLDN18.2-positive cancer comprising cancer cells expressing CLDN18.2 is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer such as non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, liver cancer, head and neck cancer, and gallbladder cancer and their metastases, particularly gastric cancer metastases, e.g., Krukenberg tumor, peritoneal metastasis, and lymph node metastasis. In one embodiment, the cancer is adenocarcinoma, particularly advanced adenocarcinoma. Particularly preferred cancer diseases are adenocarcinoma of the stomach, esophagus, pancreatic duct, bile duct, lung, and ovary. In one embodiment, the cancer is selected from the group consisting of gastric cancer, esophageal cancer, particularly lower esophageal cancer, cancer of the esophagogastric junction, and gastroesophageal cancer. In a particularly preferred embodiment, the cancer is gastroesophageal cancer, e.g., metastatic, refractory, or recurrent advanced gastroesophageal cancer. In one embodiment, the CLDN18.2-positive tumor is a tumor of the above cancer type.
[0168] An embodiment relating to a CLDN18.2-positive tumor or a cancer cell expressing CLDN18.2 preferably involves the use of an antibody having the ability to bind to CLDN18.2. In one embodiment, the antibody having the ability to bind to CLDN18.2 is a monoclonal antibody, a chimeric antibody, or a humanized antibody or a fragment of an antibody.
[0169] According to the present invention, "carcinoma" is a malignant tumor derived from epithelial cells. This group represents the most common cancers, including common forms of breast cancer, prostate cancer, lung cancer, and colon cancer.
[0170] "Adenocarcinoma" is cancer that originates in glandular tissue. This tissue is also part of a larger tissue category known as epithelial tissue. Epithelial tissue includes the skin, glands, and various tissues that line the body's cavities and organs. Embryologically, epithelium is derived from the ectoderm, endoderm, and mesoderm. To be classified as adenocarcinoma, cells do not necessarily have to be part of a gland, as long as they possess secretory properties. This form of adenoma can occur in some higher mammals, including humans. Well-differentiated adenocarcinomas tend to resemble the glandular tissue from which they originated, whereas poorly differentiated ones do not. By staining cells from a biopsy, a pathologist will determine whether the tumor is adenocarcinoma or another type of cancer. Due to the nature of glands, which are found everywhere in the body, adenocarcinoma can occur in many tissues. While not every gland may secrete the same substance, as long as the cells have exocrine functions, they are considered glandular, and thus the malignant form is named adenocarcinoma. Malignant adenocarcinoma invades other tissues and often metastasizes if given enough time to do so. Ovarian adenocarcinoma is the most common type of ovarian carcinoma. It includes serous and progressive adenocarcinoma, clear cell adenocarcinoma, and endometrioid adenocarcinoma.
[0171] "Metastasis" refers to the spread of cancer cells from their original location to another part of the body. The formation of metastasis is a highly complex process involving the separation of malignant cells from the primary tumor, their infiltration into the extracellular matrix, their infiltration into the endothelial basement membrane, their infiltration into body cavities and blood vessels, their transport by the blood, and their infiltration into target organs. Finally, the growth of new tumors at the target site depends on neovascularization. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may retain and develop metastatic potential. In one embodiment, according to the present invention, the term "metastasis" relates to "distant metastasis" associated with metastasis away from the primary tumor and the local lymph node system. In one embodiment, according to the present invention, the term "metastasis" relates to lymph node metastasis. A specific form of metastasis that can be treated using the therapeutic regimen of the present invention is metastasis originating from gastric cancer as the primary site. In a preferred embodiment, such gastric cancer metastasis is a Krukenberg tumor, peritoneal metastasis, and / or lymph node metastasis.
[0172] Refractory cancer is a malignant tumor in which specific treatment is ineffective, does not respond during the initial stages of treatment, or becomes unresponsive over time. The terms "refractory," "unresponsive," and "resistant" are used interchangeably in this institution.
[0173] Cruckenberg tumors are rare metastatic ovarian tumors, accounting for 1 to 2 percent of all ovarian tumors. The prognosis for Cruckenberg tumors remains very poor, and there are no established treatments for them. Cruckenberg tumors are metastatic signetoid adenocarcinomas of the ovary. The stomach is the primary site in most cases of Cruckenberg tumors (70%). Carcinomas of the colon, cecum, and breast (primarily invasive lobular carcinomas) are the next most common primary sites. Rare cases of Cruckenberg tumors originating from carcinomas of the gallbladder, bile ducts, pancreas, small intestine, ampulla of Pater, cervical cancer, and bladder / urachal ducts have been reported.
[0174] As used herein, the term "surgery" includes the removal of a tumor during surgery. This is a common treatment for cancer. A surgeon may remove the tumor using local excision.
[0175] As used herein, the term "chemotherapy" means the use of a chemotherapy agent or a combination of chemotherapy agents, preferably meaning stopping the growth of cancer cells by killing cells or stopping their division. When chemotherapy is administered orally or by intravenous or intramuscular injection, the drug enters the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is administered directly into a body cavity, such as the cerebrospinal fluid, trachea, or abdomen, the drug primarily affects the cells in that area (local chemotherapy).
[0176] The chemotherapy agent according to the present invention comprises a cell proliferation inhibitor compound and a cytotoxic compound. Traditional chemotherapy agents act by killing rapidly dividing cells, which is one of the major characteristics of most cancer cells. Furthermore, this implies that chemotherapy also harms cells that divide rapidly under normal conditions, such as those in the bone marrow, digestive tract, and hair follicles. This results in the most common side effects of chemotherapy. According to the present invention, the term "chemotherapy" preferably does not include antibodies that target proteins abnormally expressed in cancer cells (tumor antigens) and act by mobilizing the patient's immune system to destroy the tumor cells. However, antibodies that target proteins abnormally expressed in cancer cells (tumor antigens) and act through a therapeutic portion or agent conjugated to an antibody may be considered a form of chemotherapy. However, in the strictest sense, the term "chemotherapy" according to the present invention does not include targeted therapy.
[0177] According to the present invention, the term "chemotherapy agent" comprises taxanes, platinum compounds, nucleoside analogs, camptothecin analogs, anthracyclines, etoposides, bleomycin, vinorelbine, cyclophosphamide, and combinations thereof. According to the present invention, a reference to a chemotherapy agent comprises any prodrug, such as an ester, a salt or derivative such as a conjugate of said agent. Examples include a carrier material and a conjugate of said agent, such as protein-conjugated paclitaxel, such as albumin-conjugated paclitaxel. Preferably, the salt of said agent is pharmaceutically acceptable.
[0178] Taxanes are a class of diterpene compounds that originated from natural sources, such as plants of the genus Taxus, although some are also artificially synthesized. The primary mechanism of action of taxane-class drugs is the inhibition of cell division by disrupting microtubule function. Taxanes include docetaxel (Taxotere) and paclitaxel (Taxol).
[0179] According to the present invention, the term "docetaxel" refers to a compound having the following chemical formula:
[0180]
[0181] In particular, the term "docetaxel" refers to the compound 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-en-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)-amino]-2-hydroxy-3-phenylpropanoate}.
[0182] According to the present invention, the term "paclitaxel" refers to a compound having the following chemical formula:
[0183]
[0184] In particular, the term "paclytaxel" refers to the compound (2α,4α,5β,7β,10β,13α)-4,10-bis-(acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate.
[0185] According to the present invention, the term "platinum compound" refers to a compound containing platinum within its structure, such as a platinum complex, and includes compounds such as cisplatin, carboplatin, and oxaliplatin.
[0186] The term "cisplatin" or "cisplatinum" refers to a compound of the following chemical formula. Sis - Refers to diammindichloroplatinum(II) (CDDP):
[0187]
[0188] The term "carboplatin" refers to the compound cis-diammine(1,1-cyclobutanedicarboxylatto)platinum(II) of the following chemical formula:
[0189]
[0190] The term "oxaliplatin" refers to a compound that is a platinum compound complexed with a diaminocyclohexane carrier ligand of the following chemical formula:
[0191]
[0192] In particular, the term "oxaliplatin" refers to the compound [(1R,2R)-cyclohexane-1,2-diamine](ethandioato-O,O')platinum(II). Additionally, injectable oxaliplatin is marketed under the trade name Eloxatine.
[0193] The term "nucleoside analogue" refers to structural analogues of nucleosides, a category that includes both purine analogues and pyrimidine analogues.
[0194] The term "gemcitabine" is a compound that is a nucleoside analog of the following chemical formula:
[0195]
[0196] In particular, this term refers to the compound 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidine-2(1H)-one or 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidine-2-one.
[0197] The term "nucleoside analog" includes fluoropyrimidine derivatives, such as fluorouracil and its prodrugs. The term "fluorouracil" or "5-fluorouracil (5-FU or f5U)" (marketed under the trademarks Adrucil, Carac, Efudix, Efudex, and Fluoroplex) is a compound that is a pyrimidine analog of the following chemical formula:
[0198]
[0199] In particular, this term refers to the compound 5-fluoro-1H-pyrimidine-2,4-dione.
[0200] The term "capecitabine" (Xeloda, Roche) refers to a chemotherapeutic agent that is a prodrug converted to 5-FU in tissues. Capecitabine, which can be administered orally, has the following chemical formula:
[0201]
[0202] In particular, this term refers to the compound pentyl[1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidine-4-yl]carbamate.
[0203] The terms "polynic acid" or "leucovorin" refer to compounds useful as synergistic combinations with the chemotherapeutic agent 5-fluorouracil. Accordingly, when the administration of 5-fluorouracil or its prodrug is referred to herein, in one embodiment, said administration may include co-administration with polynic acid. Polynic acid has the following chemical formula:
[0204]
[0205] In particular, this term refers to the compound (2S)-2-{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8-tetrahydro-1H-pterydin-6-yl)methylamino]benzoyl]amino}pentanedionic acid.
[0206] According to the present invention, the term "camtothecin analogue" refers to a derivative of the compound camtothecin (CPT; (S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione). Preferably, the term "camtothecin analogue" refers to a compound comprising the following structure:
[0207]
[0208] According to the present invention, a preferred camtothecin analog is an inhibitor of the DNA enzyme topoisomerase I (topo I). A preferred camtothecin analog according to the present invention is irinotecan and topotecan.
[0209] Irinotecan is a drug that prevents DNA from unwinding through the inhibition of topoisomerase I. Chemically speaking, it is a semisynthetic analogue of the natural alkaloid camtothecin, which has the following chemical formula:
[0210]
[0211] In particular, the term "irinotecan" refers to the compound (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-9-yl-[1,4'-bipiperidine]-1'-carboxylate.
[0212] Topotecan is a topoisomerase inhibitor with the chemical formula:
[0213]
[0214] In particular, the term "topotecan" refers to the compound (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride.
[0215] Anthracyclines are a class of drugs commonly used in cancer chemotherapy that are also antibiotics. Structurally, all anthracyclines share the conventional four-ring 7,8,9,10-tetrahydrotetracen-5,12-quinone structure and generally require glycosylation at specific sites.
[0216] It is desirable for anthracyclines to cause one or more of the following mechanisms of action: 1. To inhibit DNA and RNA synthesis by inserting between base pairs of DNA / RNA strands, thereby preventing the replication of rapidly growing cancer cells. 2. To inhibit topoisomerase II enzymes and prevent the relaxation of supercoordinated DNA, thereby blocking DNA transcription and replication. 3. To generate iron-mediated free oxygen radicals that damage DNA and cell membranes.
[0217] According to the present invention, the term "anthracycline" relates to an anticancer agent preferably for inducing apoptosis by inhibiting DNA recombination in topoisomerase II.
[0218] Examples of anthracyclines and anthracycline analogs include, but are not limited to, daunorubicin (daunomycin), doxorubicin (adriamycin), epirubicin, isarubicin, rodomycin, pirarubicin, valrubicin, N-trifluoro-acetyl doxorubicin-14-valerate, aclassinomycin, morpholinodoxorubicin (morpholino-DOX), cyanomorpholino-doxorubicin (cyano-morpholino-DOX), 2-pyrrolino-doxorubicin (2-PDOX), 5-iminodaunomycin, mitoxantrone, and aclassinomycin A (aclarubicin). Mithoxantrone is a member of the anthracendione family of compounds, which are anthracycline analogs that lack a portion of the anthracycline sugar but maintain a planar polycyclic aromatic ring structure that allows insertion into DNA.
[0219] Epirubicin is specifically considered as an anthracycline in the context of the present invention. Epirubicin is an anthracycline drug having the following chemical formula:
[0220]
[0221] In addition, it is marketed in the United States under the brand name Ellence, and in other countries under the brand names Pharmorubicin or Epirubicin Ebewe. In particular, the term "epirubicin" refers to the compound (8R,10S)-10-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-oxane-2-yl]oxy-6,11-dihydroxy-8-(2-hydroxyacetyl)-1-methoxy-8-methyl-9,10-dihydro-7H-tetracene-5,12-dione. Epirubicin is preferred over doxorubicin, the most widely used anthracycline in some chemotherapy regimens, because it has been shown to have fewer side effects.
[0222] The term "etoposide" refers to semi-synthetic derivatives of podophyllotoxin that exhibit antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces cleavage in double-stranded DNA and prevents repair by topoisomerase II binding. The accumulated DNA breaks block entry into the mitotic phase of cell division, thereby inducing apoptosis. Etoposide has the following chemical formula:
[0223]
[0224] In particular, this term refers to the compound 4'-demethyl-epidophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside], 4'-(dihydrogen phosphate).
[0225] The term "bleomycin" refers to a glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. When used as an anticancer agent, it works by destroying DNA. Bleomycin preferably comprises a compound having the following chemical formula:
[0226]
[0227] The term "vinorelbine" refers to a semi-synthetic vinca alkaloid and an anti-mitotic chemotherapy drug used as a treatment for certain types of cancer, including breast cancer and non-small cell lung cancer. Vinorelbine preferably comprises a compound having the following chemical formula:
[0228]
[0229] Cyclophosphamide is a nitrogen mustard alkylating agent derived from an oxazoporin group. The primary use of cyclophosphamide is in combination with other chemotherapy agents for the treatment of certain forms of cancer. Cyclophosphamide preferably comprises compounds having the following chemical formula:
[0230]
[0231] In the context of the present invention, the term "radiation therapy" refers to the use of high-energy X-rays or other types of radiation to kill cancer cells or inhibit their growth. There are two types of radiation therapy. External radiation therapy involves sending radiation toward the cancer using a machine located outside the body. Internal radiation therapy involves using radioactive material sealed in a needle, seed, wire, or catheter that is placed directly inside or near the cancer. The method of radiation therapy is applied differently depending on the type and stage of the cancer to be treated.
[0232] According to the present invention, the term “targeted therapy” relates to any therapy that may be used to preferentially target diseased cells, such as cancer cells, but to target or not target diseased cells to a lesser extent. Targeting of diseased cells preferably causes a reduction and / or impairment of the proliferation or viability of the diseased cells. Such therapies comprise i) antibodies, antibody fragments, and proteins (e.g., antibodies or antibody conjugates to CLDN18.2 as described herein) that are naked or conjugated to a therapeutic portion targeting a specific cell surface target on diseased cells, such as a tumor antigen, e.g., CLDN18.2, or ii) small molecules that inhibit the proliferation or viability of diseased cells. In certain embodiments, the agent binds to an antigen that is expressed at a higher level on diseased cells than on normal stem cells. In certain embodiments, the agent binds specifically to a tumor antigen. Traditional chemotherapy or radiotherapy is not considered “targeted therapy” even though it often targets tumors. Additionally, the term "antibody therapy" according to the present invention preferably does not include a therapy comprising an antibody, fragment, or derivative thereof conjugated to a therapeutic portion, but merely relates to a therapy comprising an antibody, fragment, or derivative thereof that acts by mobilizing the patient's immune system to destroy tumor cells.
[0233] The term "antigen" relates to a preparation comprising an epitope that causes an immune response to be generated and / or induced. The term "antigen" particularly includes proteins, peptides, polysaccharides, nucleic acids, particularly RNA and DNA, and nucleotides. Additionally, the term "antigen" includes a preparation that acquires only antigenicity and sensitizing properties through transformation (e.g., by intervening within a molecule or by consolidating into a protein body). The antigen or a processed product thereof is preferably recognizable by T or B cell receptors or immunoglobulin molecules such as antibodies. In a preferred embodiment, the antigen is a disease-associated antigen, such as a tumor antigen like CLDN18.2.
[0234] In the context of the present invention, the term “tumor antigen” or “tumor-associated antigen” relates to an antigen present on a tumor cell. Preferably, the antigen is present on the tumor cell, such as on the surface of the tumor cell. Preferably, the “tumor antigen” is expressed by the tumor cell. In one embodiment, the term “tumor antigen” relates to a protein that is abnormally expressed in the tumor cell compared to normal cells, i.e., non-tumor cells. For example, expression may be found only in the tumor cell but not in normal cells, i.e., non-tumor cells, or the expression level may be higher in the tumor cell compared to normal cells, i.e., non-tumor cells. In one embodiment, the term “tumor antigen” relates to a protein that is specifically expressed in a limited number of tissues and / or organs or at a specific stage of development under normal conditions and is expressed or abnormally expressed in one or more tumor or cancer tissues. In the context of the present invention, the tumor antigen is preferably associated with the cell surface of the cancer cell and is preferably not expressed in normal tissues and normal cells, or is rarely expressed or expressed at a lower level. Preferably, according to the present invention, a tumor antigen is not expressed in cells when the expression level is below the detection limit and / or when the expression level is too low to allow binding by a tumor antigen-specific antibody added to the cells. A particularly preferred tumor antigen according to the present invention is CLDN18.2.
[0235] According to the present invention, the term "tumor antigen-positive cancer" or "tumor antigen-positive tumor" or a similar term means cancer or tumor comprising cancer or tumor cells expressing a tumor antigen, and preferably means cancer or tumor comprising cancer or tumor cells expressing a tumor antigen on the surface of said cancer cells or tumor. The tumor antigen is located on the surface of said cell and is expressed on the cell surface if binding by a tumor antigen-specific antibody added to the cell is permissible.
[0236] In a preferred embodiment of the present invention, "tumor antigen-positive cancer" or "tumor antigen-positive tumor" is "CLDN18.2-positive cancer" or "CLDN18.2-positive tumor." According to the present invention, the term "CLDN18.2-positive cancer" or "CLDN18.2-positive tumor" means cancer or tumor comprising cancer or tumor cells expressing CLDN18.2, and preferably means cancer or tumor comprising cancer or tumor cells expressing CLDN18.2 on the surface of said cancer cells or tumor cells.
[0237] "Cell surface" is used in its ordinary sense in the art and thus includes the exterior of a cell where binding by proteins and other molecules is permitted.
[0238] In the context of the present invention, the term “extracellular portion” refers to a portion of a molecule, such as a protein, that faces the extracellular space of the cell and is preferably accessible from outside the cell by an antigen-binding molecule, such as an antibody, located outside the cell. Preferably, this term refers to one or more extracellular loops or domains or fragments thereof.
[0239] According to the present invention, CLDN18.2 is substantially not expressed in cells when the expression level is lower compared to the expression in gastric cells or gastric tissue. Preferably, the expression level is less than 10% of the expression in gastric cells or gastric tissue, preferably less than 5%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05%, or even lower. Preferably, CLDN18.2 is substantially not expressed in cells when the expression level exceeds the expression level in non-cancerous tissues other than the stomach by only 2 times, preferably 1.5 times, and preferably does not exceed the expression level in said non-cancerous tissues. Preferably, CLDN18.2 is substantially not expressed in cells when the expression level is below the detection limit and / or when the expression level is too low to allow binding by a CLDN18.2-specific antibody added to the cells.
[0240] According to the present invention, CLDN18.2 is expressed in cells when the expression level exceeds the expression level in non-cancerous tissues other than the stomach by more than twofold, preferably more than tenfold, one hundredfold, one thousandfold, or one thousand thousandfold. Preferably, CLDN18.2 is expressed in cells when the expression level exceeds a detection limit and / or when the expression level is sufficiently high to allow binding by a CLDN18.2-specific antibody added to the cells. Preferably, CLDN18.2 expressed in cells is expressed or exposed on the surface of said cells.
[0241] The term "epitope" refers to an antigenic determinant within a molecule, that is, a part of a molecule recognized by the immune system, for example, by antibodies. For instance, an epitope is a distinct three-dimensional region on an antigen recognized by the immune system. Epitopes generally consist of chemically active surface groups of a molecule, such as amino acids or sugar side chains, and typically possess specific charge properties as well as specific three-dimensional structural characteristics. Structural and non-structural epitopes are distinguished in that, in the presence of a denatured solvent, binding to the former is lost, while binding to the latter is not. The epitope of the protein preferably comprises a continuous or discontinuous portion of the protein, and its length is preferably 5 to 100, preferably 5 to 50, more preferably 8 to 30, most preferably 10 to 25 amino acids, and for example, the epitope may preferably have a length of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids.
[0242] The term “antibody” comprises any molecule comprising a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and an antigen-binding portion of such glycoprotein. The term “antibody” comprises fragments or derivatives of antibodies, including monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain antibodies, e.g., scFv, and antigen-binding antibody fragments, e.g., Fab and Fab’ fragments, without limitation, and any recombinant forms of antibodies, e.g., antibodies expressed in prokaryotes, non-glycosylated antibodies, and any antigen-binding antibody fragments and derivatives as described herein. Each heavy chain consists of a heavy chain variable region (abbreviated as VH herein) and a heavy chain constant region. Each light chain consists of a light chain variable region (abbreviated as VL herein) and a light chain constant region. The VH and VL regions may be further subdivided into a more conserved region, referred to as a framework region (FR), and a hypervariable region, referred to as a complementation determining region (CDR), which is interspersed with a more conserved region. Each VH and VL consists of three CDRs and four FRs arranged from the amino-terminus to the carboxy-terminus in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The conserved region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0243] The term “monoclonal antibody” as used herein refers to a preparation of antibody molecules of a single molecular composition. Monoclonal antibodies exhibit single-binding specificity and affinity. In one embodiment, the monoclonal antibody is produced by hybrid cells comprising B cells obtained from a non-human animal, e.g., a mouse, fused to immortalized cells.
[0244] As used herein, the term “recombinant antibody” comprises all antibodies produced, expressed, created, or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that have been transgenic or transchromosomal to an immunoglobulin gene or from hybrid cells produced therefrom, (b) antibodies isolated from host cells transformed to express antibodies, e.g., transfectomas, (c) antibodies isolated from a library of recombinant antibodies, and (d) antibodies produced, expressed, created, or isolated by any other means including splicing an immunoglobulin gene sequence to another DNA sequence.
[0245] As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies have amino acid residues not encoded by human germline immunoglobulin sequences (e.g., In vitro Mutations introduced by random or site-specific mutagenesis or In vivo It may include mutations introduced by somatic mutations.
[0246] The term "humanized antibody" refers to a molecule having an antigen-binding site substantially derived from a non-human immunoglobulin, wherein the remainder of the molecule's immunoglobulin structure is based on the structure and / or sequence of a human immunoglobulin. The antigen-binding site may comprise only a complete variable domain fused to a constant domain or a complementation determining region (CDR) transplanted into an appropriate framework region within the variable domain. The antigen-binding site may be wild-type or modified by one or more amino acid substitutions, for example, to be modified to be more similar to human immunoglobulin. Some forms of humanized antibodies preserve all CDR sequences (e.g., a humanized mouse antibody containing all six CDRs from a mouse antibody). Other forms have one or more CDRs modified relative to the original antibody.
[0247] The term "chimeric antibody" refers to antibodies in which a portion of the amino acid sequences of each of the heavy and light chains is homologous to corresponding sequences in antibodies derived from a specific species or belonging to a specific class, while the remaining segment of the chain is homologous to a corresponding sequence in another chain. Typically, the variable regions of the light and heavy chains mimic the variable regions of antibodies derived from one mammalian species, while the constant regions are homologous to the sequences of antibodies derived from another. One clear advantage of this chimeric form is that the variable region can be conveniently derived from currently known sources, such as readily available B-cells or hybrid cells from non-human host organisms, in combination with a constant region derived, for example, from human cell preparations. While the variable region offers the advantage of ease of manufacture and specificity is not affected by the source, a human constant region is less likely to elicit an immune response from a human subject when injected than antibodies with a constant region from a non-human source. However, the definition is not limited to these specific examples.
[0248] Antibodies may be derived from different species, including but not limited to mice, rats, rabbits, guinea pigs, and humans.
[0249] The antibodies described herein include IgA antibodies, such as IgA1 or IgA2, IgG1, IgG2, IgG3, IgG4, IgE, IgM, and IgD antibodies. In various embodiments, the antibody is an antibody of IgG1, and more specifically, IgG1, kappa or IgG1, lambda isotypes (e.g., IgG1, κ, λ), IgG2a antibody (e.g., IgG2a, κ, λ), IgG2b antibody (e.g., IgG2b, κ, λ), IgG3 antibody (e.g., IgG3, κ, λ), or IgG4 antibody (e.g., IgG4, κ, λ).
[0250] As used herein, "heterologous antibody" is defined in relation to the genetically modified organism that produces such antibody. This term refers to an antibody having an amino acid sequence or coding nucleic acid sequence corresponding to that found in an organism that is not the genetically modified organism, and generally refers to an antibody derived from species other than the genetically modified organism.
[0251] As used herein, "heterohybrid antibody" refers to an antibody having light and heavy chains of different organism origin. For example, an antibody having a human heavy chain combined with a murine light chain is a heterohybrid antibody.
[0252] The antibodies described herein are preferably isolated. As used herein, "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds to a tumor antigen is substantially free of antibodies that specifically bind to antigens other than the tumor antigen). However, an isolated antibody that specifically binds to an epitope, isoform, or variant of a human tumor antigen may have cross-reactivity to other related antigens from other species (e.g., tumor antigen species homologs). Additionally, the isolated antibody may not substantially contain other cellular material and / or chemical substances. In one embodiment of the invention, a combination of "isolated" monoclonal antibodies has different specificities and relates to antibodies combined in a clearly defined composition or mixture.
[0253] The terms “antigen-binding portion” (or simply “binding portion”) or “antigen-binding fragment” (or simply “binding fragment”), or similar terms, refer to one or more fragments of an antibody that possess the ability to specifically bind to an antigen. This indicates that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments included in the term “antigen-binding portion” of an antibody include: (i) the Fab fragment, a monovalent fragment consisting of VL, VH, CL, and CH domains; (ii) the F(ab’)2 fragment, a divalent fragment comprising two Fab fragments connected by disulfide crosslinking at the hinge region; (iii) the Fd fragment, consisting of VH and CH domains; (iv) the Fv fragment, consisting of VL and VH domains of a single arm of the antibody; (v) the dAb fragment, consisting of a VH domain (Ward et al., (1989) Nature 341: 544-546); and (vi) the separated complementarity determining region (CDR). and (vii) combinations of two or more separate CDRs that can be optionally linked by a synthetic linker. Additionally, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be linked by a synthetic linker using a recombination method to enable the production of a single protein chain (known as single-stranded Fv (scFv); see, e.g., Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883) in which the VL and VH regions are paired to form a monovalent molecule. Furthermore, these single-stranded antibodies are intended to be included in the term "antigen-binding fragment" of an antibody.Another example is a binding-domain immunoglobulin fusion protein comprising (i) a binding domain polypeptide fused to an immunoglobulin hinge domain polypeptide, (ii) an immunoglobulin heavy chain CH2 constant region fused to the hinge region, and (iii) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region. The binding domain polypeptide may be a heavy chain variable region or a light chain variable region. Binding-domain immunoglobulin fusion proteins are further disclosed in U.S. Patent Application No. 2003 / 0118592 and U.S. Patent Application No. 2003 / 0133939. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and said fragments are screened for utility in the same manner as intact antibodies.
[0254] The term "binding domain" in relation to the present invention is characterized as a structure, e.g., an antibody, that binds to or interacts with a given target structure / antigen / epitope. Accordingly, the binding domain according to the present invention represents an "antigen-interaction-site."
[0255] For the purposes of the present invention, all antibodies and derivatives of antibodies, such as antibody fragments, as described herein are included in the term “antibody.” The term “antibody derivative” refers to any modified form of an antibody, for example, a conjugate of an antibody with another preparation or an antibody, or an antibody fragment.
[0256] Naturally occurring antibodies are generally monospecific, meaning they bind to a single antigen. The present invention comprises antibodies that bind to target cells (by engaging a tumor antigen) and a second entity, such as cytotoxic cells (e.g., by engaging a CD3 receptor). The antibodies of the present invention may be multispecific, such as bispecific, trispecific, and quadrative specific.
[0257] The term "bispecific molecule" is intended to include a preparation having two different binding specificities. For example, the molecule may bind to or interact with (a) a cell surface antigen and (b) a receptor on the surface of an effector cell, such as an Fc receptor. The term "multispecific molecule" is intended to include a preparation having more than two different binding specificities. For example, the molecule may bind to or interact with (a) a cell surface antigen, (b) a receptor on the surface of an effector cell, such as an Fc receptor, and (c) at least one other component. Accordingly, the term "antibody against tumor antigen" includes, but is not limited to, bispecific, trispecific, quadrspecific, and other multispecific molecules against tumor antigens and other targets such as Fc receptors on effector cells. Additionally, the term "bispecific antibody" also includes diabodies. Diabodies are divalent bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but because they are too short to pair the two domains on the same chain, a linker is used to pair the domains with the complementary domain of another chain, thereby creating two antigen-binding sites (see, e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, RJ, et al. (1994) Structure 2: 1121-1123).
[0258] According to the present invention, antibodies may exert their therapeutic effects by mobilizing the patient's immune system to destroy tumor cells and / or through a therapeutic portion or agent bound to the antibody. For the purposes of the present invention, such antibody conjugates may be considered to be included in the term "chemotherapy agent," but antibodies that exert their therapeutic effects by mobilizing the patient's immune system to destroy tumor cells are not.
[0259] In the context of the present invention, the antibody may preferably act by mobilizing the patient's immune system to destroy tumor cells, that is, when the antibody binds to its target, such as a tumor antigen on a diseased cell, it induces an immune effector function as described herein. Preferably, the immune effector function acts on cells such as cancer cells that possess tumor antigens such as CLDN18.2 on their surfaces.
[0260] In the context of the present invention, the term “immune effector function” includes any function mediated by a component of the immune system that causes inhibition of tumor growth and / or inhibition of tumor development, including, for example, inhibition of tumor dissemination and metastasis. Preferably, the immune effector function causes apoptosis of cancer cells. These functions include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), induction of programmed cell death in cells carrying tumor antigens, cytolysis of cells carrying tumor antigens, and / or inhibition of proliferation of cells carrying tumor antigens. A binder may also exert its effect simply by binding to a tumor antigen on the surface of a cancer cell. For example, an antibody may block the function of a tumor antigen or induce programmed cell death by binding to a tumor antigen on the surface of a cancer cell.
[0261] Antibody-dependent cell-mediated cytotoxicity
[0262] ADCC describes the cell-killing ability of effector cells, particularly lymphocytes, which preferably require target cells to be labeled by antibodies.
[0263] ADCC preferably occurs when an antibody binds to an antigen on a tumor cell and the antibody's Fc domain binds to the Fc receptor (FcR) on the surface of an immune effector cell. Several families of Fc receptors have been identified, and specific cell populations express characteristically defined Fc receptors. ADCC can be viewed as a mechanism that directly induces varying degrees of immediate tumor destruction, exhibiting antigen presentation and the induction of tumor-induced T cell responses. Preferably, ADCC's In vivo Induction will exhibit tumor-directed T-cell responses and host-derived antibody responses.
[0264] Complement-dependent cytotoxicity
[0265] CDC is another cell-killing mechanism that can be directed by antibodies. IgM is the most effective isoform for complement activation. Additionally, both IgG1 and IgG3 are highly effective in inducing CDC via the classical complement-activation pathway. Preferably, in this cascade, the formation of the antigen-antibody complex involves the C of participating antibody molecules, such as IgG molecules. H This causes the exposure of multiple closely spaced C1q binding sites on the 2 domain (C1q is one of the three subcomponents of complement C1). Preferably, these exposed C1q binding sites convert previously low-affinity C1q-IgG interactions into high-avidity binding activities, which trigger a series of events involving a series of other complement proteins and induce the proteolytic release of effector-cell chemotactic agents / activators C3a and C5a. Preferably, the complement cascade terminates with the formation of a membrane injury complex, which creates pores in the cell membrane to facilitate the free passage of water and solutes across the membrane.
[0266] According to the present invention, to inhibit tumor growth and / or tumor development, an antibody may be conjugated to a therapeutic part or agent such as a cytotoxin, a drug (e.g., an immunosuppressant), or a radioisotope. The cytotoxin or cytotoxic agent comprises any agent that is harmful to cells and particularly kills cells. Examples include taxol, cytocalcin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracindione, mitoxantrone, mitramycin, actinomycin D, amanitin, 1-dihydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologues thereof. Suitable therapeutic agents for forming antibody conjugates include metabolic antagonists (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabin, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepah chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mitramycin, and anthramycin (AMC), and anti-mitotic agents (e.g., vincristine and vinblastine), but are not limited thereto. In a preferred embodiment, the therapeutic agent is a cytotoxic agent or a radiotoxic agent. In another embodiment, the therapeutic agent is an immunosuppressant. In another embodiment, the therapeutic agent is GM-CSF. In a preferred embodiment, the therapeutic agent is doxorubicin, cisplatin, bleomycin, sulfate, carmustine, chlorambucil, cyclophosphamide, or lysine A.
[0267] In addition, antibodies can be conjugated to radioisotopes, for example, iodine-131, yttrium-90, or indium-111, to produce cytotoxic radiopharmaceuticals.
[0268] The antibody conjugate of the present invention may be used to modify a given biological response, and the drug portion should not be interpreted as being limited to classical chemotherapy agents. For example, the drug portion may be a protein or polypeptide having the desired biological activity. Such proteins may include, for example, enzymatically active toxins, or their active fragments, such as abrine, lysine A, Pseudomonas exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor or interferon-γ; or biological response modifiers such as lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony-stimulating factor ("GM-CSF"), granulocyte colony-stimulating factor ("G-CSF"), or other growth factors.
[0269] 이러한 치료적 일부분을 항체에 접합시키는 기술은 잘 공지되어 있으며, 예를 들어, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pincheraet al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), 및 Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62: 119-58 (1982)를 참고한다.
[0270] The term "antibody against tumor antigen" or a similar term relates to an antibody having the ability to bind to a tumor antigen or an antibody having such ability. The term "binding" according to the present invention preferably relates to specific binding.
[0271] According to the present invention, an antibody has a significant affinity for a predetermined target and can bind to a predetermined target if it binds to the predetermined target in a standard test. "Affinity" or "binding affinity" is often the equilibrium dissociation constant (K D It is measured as ). Preferably, the term "significant affinity" is the dissociation constant (K D ) is 10 -5 M or less, 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 M or less, 10 -11 M or less, or 10 -12 It refers to a combination for a specified target that is less than or equal to M.
[0272] The antibody cannot (substantially) bind to the target unless it exhibits significant affinity for the target, does not bind significantly to the target in a standard test, and in particular does not bind detectably. Preferably, the antibody does not bind detectably to the target if it is present at a concentration of 2 or less, preferably 10, more preferably 20, in particular 50 or 100 μg / ml or more. Preferably, K for the antibody binding to a predetermined bindable target D At least 10 times, 100 times, or 10 times more than 3 -Pear, 10 4 -Pear, 10 5 - times, or 10 6 - K, which is the double excess D When binding to the above target having, the antibody does not have a significant affinity for the target. For example, K regarding the binding of the antibody to a target to which the antibody can bind. DGa 10 -7 If M, K for binding to a target where the antibody has no significant affinity D is at least 10 -6 M, 10 -5 M, 10 -4 M, 10 -3 M, 10 -2 M, or 10 -1 It could be M.
[0273] An antibody is specific to a specified target if it can bind to the following specified target but cannot bind to other targets, that is, it does not have a significant affinity for other targets and does not bind significantly to other targets in standard tests. According to the present invention, an antibody is specific to a tumor antigen if it can bind to a tumor antigen but cannot (substantially) bind to other targets. Preferably, the antibody is specific to a tumor antigen if its affinity and binding to these other targets do not significantly exceed the affinity or binding to tumor antigen-unrelated proteins, such as bovine serum albumin (BSA), casein, human serum albumin (HSA), or non-tumor antigen transmembrane proteins, such as MHC molecules or transferrin receptors, or any other specific polypeptide. Preferably, the antibody is K for binding to non-specific targets. D At least 10 times, 100 times, or 10 times more than 3 -Pear, 10 4 -Pear, 10 5 - times, or 10 6 K less than - times D When binding to a target having, the formulation is specific for a given target. For example, K regarding the binding of an antibody to a specific target. D Ga 10 -7 If M, K for binding to a non-specific target D is at least 10 -6 M, 10 -5 M, 10 -4 M, 10 -3 M, 10 -2M, or 10 -1 It could have been M.
[0274] The binding of an antibody to a target can be determined experimentally using any suitable method; for example, refer to Berzofsky et al., “Antibody-Antigen Interactions” In Fundamental Immunology, Paul, WE, Ed., Raven Press New York, NY (1984), Kuby, Janis Immunology, WH Freeman and Company New York, NY (1992), and the methods described herein. Affinity can be easily determined using conventional techniques, such as by equilibrium dialysis; by using a BIAcore 2000 instrument using the general procedure described by the manufacturer; by radioimmunoassay using a radiolabeled target antigen; or by other methods known to those skilled in the art. Affinity data can be analyzed, for example, by the method of Scatchard et al., Ann NY Acad. ScL, 51:660 (1949). The measured affinity of a specific antibody-antigen interaction can vary when measured under different conditions, e.g., salt concentration, pH. Therefore, affinity and other antigen-binding parameters, e.g., K D , IC 50 It is preferably measured with a standardized solution of antibody and antigen and a standardized buffer.
[0275] As used herein, "homologous" refers to a class of antibodies (e.g., IgM or IgG1) encoded by a heavy chain constant region gene.
[0276] As used herein, "homogenetic switching" refers to the phenomenon in which a class or homotype of an antibody changes from one Ig class to one of the other Ig classes.
[0277] As used herein, the term “naturally occurring” applied to the subject refers to the fact that the subject can be found in nature. For example, polypeptide or polynucleotide sequences present in organisms (including viruses) that can be isolated from natural sources and have not been intentionally modified by humans in a laboratory are naturally occurring.
[0278] As used herein, the term “rearranged” refers to the stereoconfiguration of a heavy or light chain immunoglobulin locus in which the V segment is located directly adjacent to the DJ or J segment at a stereoconfiguration in which the V segment essentially encodes a complete VH or VL domain, respectively. The rearranged immunoglobulin (antibody) locus can be identified by comparison with germline DNA; and the rearranged locus will have at least one recombinant heptameric / naptameric homology element.
[0279] As used herein with respect to the V segment, the terms "unrearranged" or "germline stereoconfiguration" refer to a stereoconfiguration in which the V segment is not reassembled to be directly adjacent to the D or J segment.
[0280] Preferably, binding of an antibody to a tumor antigen to a cell expressing a tumor antigen induces or mediates the death of the cell expressing the tumor antigen. The cell expressing the tumor antigen is preferably a cancer cell, and in particular, a cell of the cancer disease described herein. Preferably, the antibody induces or mediates the death of the cell by inducing one or more of complement-dependent cytotoxicity (CDC)-mediated lysis, antibody-dependent cytotoxicity (ADCC)-mediated lysis, apoptosis, and inhibition of proliferation of the cell expressing the tumor antigen. Preferably, ADCC-mediated lysis of the cell occurs in the presence of an effector cell, which in certain embodiments is selected from the group consisting of monocytes, mononuclear cells, NK cells, and PMNs. Inhibition of cell proliferation can be measured in vitro by determining cell proliferation in an assay using bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU). BrdU is a synthetic nucleoside that is an analog of thymidine and is incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), and can be replaced by thymidine during DNA replication. For example, detecting the contained chemical using an antibody specific to BrdU indicates that the cell was actively replicating this DNA.
[0281] In a preferred embodiment, the antibody described herein may be characterized by one or more of the following characteristics:
[0283] *a) Specificity for tumor antigens;
[0284] b) Binding affinity for tumor antigens of about 100 nM or less, preferably about 5-10 nM or less, and more preferably about 1-3 nM or less;
[0285] c) Ability to induce or mediate CDC in tumor antigen-positive cells;
[0286] d) Ability to induce or mediate ADCC in tumor antigen-positive cells;
[0287] e) Ability to inhibit the growth of tumor antigen-positive cells;
[0288] f) Ability to induce programmed cell death in tumor antigen-positive cells.
[0289] In one embodiment, the antibody against the tumor antigen has the ability to bind to an epitope present on the tumor antigen, preferably an epitope located within the extracellular domain of the tumor antigen. Preferably, the antibody against the tumor antigen is specific to the tumor antigen. Preferably, the antibody against the tumor antigen binds to the tumor antigen expressed on the cell surface. In a particularly preferred embodiment, the antibody against the tumor antigen binds to an intrinsic epitope of the tumor antigen present on the surface of a living cell.
[0290] According to the present invention, an antibody having the ability to bind to CLDN18.2 or an antibody against CLDN18.2 is an antibody capable of binding to an epitope present in CLDN18.2, preferably an epitope located within the extracellular domain of CLDN18.2, particularly within the first extracellular domain, preferably at amino acid positions 29 to 78 of CLDN18.2. In a specific embodiment, the antibody having the ability to bind to CLDN18.2 is an antibody capable of binding to (i) an epitope on CLDN18.2 that is not present on CLDN18.1, preferably SEQ ID NOs 3, 4, and 5; (ii) an epitope located on CLDN18.2-loop 1, preferably SEQ ID NO. 8; (iii) an epitope located on CLDN18.2-loop 2, preferably SEQ ID NO. 10; (iv) an epitope located on CLDN18.2-loop D3, preferably SEQ ID NO. 11; (v) an epitope comprising CLDN18.2-loop 1 and CLDN18.2-loop D3; or (vi) a non-glycosylated epitope located on CLDN18.2-loop D3, preferably SEQ ID NO. 9.
[0291] According to the present invention, an antibody having the ability to bind to CLDN18.2 is preferably an antibody having the ability to bind to CLDN18.2 but not to CLDN18.1. Preferably, the antibody having the ability to bind to CLDN18.2 is specific to CLDN18.2. Preferably, the antibody having the ability to bind to CLDN18.2 is an antibody having the ability to bind to CLDN18.2 expressed on a cell surface. In a particularly preferred embodiment, the antibody having the ability to bind to CLDN18.2 binds to an intrinsic epitope of CLDN18.2 present on the surface of a living cell. Preferably, the antibody having the ability to bind to CLDN18.2 binds to one or more peptides selected from the group consisting of SEQ ID NOs 1, 3-11, 44, 46, and 48-50. Preferably, the antibody having the ability to bind to CLDN18.2 is specific to the aforementioned proteins, peptides, or immunogenic fragments or derivatives thereof. An antibody having the ability to bind to CLDN18.2 can be obtained by a method comprising the step of immunizing an animal with a protein or peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 1, 3-11, 44, 46, and 48-50, or a nucleic acid expressing said protein or peptide, or a host cell. Preferably, the antibody binds to cancer cells, particularly to cells of the aforementioned cancer types, and preferably does not bind substantially to non-cancer cells.
[0292] Preferably, binding of an antibody capable of binding to CLDN18.2 to cells expressing CLDN18.2 induces or mediates apoptosis of the cells expressing CLDN18.2. Cells expressing CLDN18.2 are preferably cancer cells and are selected from the group consisting particularly of tumorigenic gastric, esophageal, pancreatic, lung, ovarian, colon, liver, head and neck, and gallbladder cancer cells. Preferably, the antibody induces or mediates apoptosis by inducing one or more of complement-dependent cytotoxicity (CDC)-mediated lysis, antibody-dependent cytotoxicity (ADCC)-mediated lysis, apoptosis, and inhibition of proliferation of cells expressing CLDN18.2. Preferably, ADCC-mediated lysis of cells occurs in the presence of effector cells and, in certain embodiments, is selected from the group consisting of monocytes, mononuclear cells, NK cells, and PMNs.
[0293] In a preferred embodiment, an antibody having the ability to bind to CLDN18.2 may be characterized by one or more of the following characteristics:
[0294] a) Specificity for CLDN18.2;
[0295] b) Binding affinity for CLDN18.2 of about 100 nM or less, preferably about 5-10 nM or less, and more preferably about 1-3 nM or less;
[0296] c) Ability to induce or mediate CDC in CLDN18.2-positive cells;
[0297] d) Ability to induce or mediate ADCC in CLDN18.2-positive cells;
[0298] e) Ability to inhibit the growth of CLDN18.2-positive cells;
[0299] f) Ability to induce programmed cell death in CLDN18.2-positive cells.
[0300] In a particularly preferred embodiment, the antibody having the ability to bind to CLDN18.2 is produced by hybrid cells deposited at DSMZ (Mascheroder Weg 1b, 31824 Braunschweig, Germany; new address: Inhoffenstr. 7B, 31824 Braunschweig, Germany) and has the following markings and deposit numbers:
[0301] a. 182-D1106-055, deposited on October 19, 2005, accession number DSM ACC2737
[0302] b. 182-D1106-056, deposited on October 19, 2005, accession number DSM ACC2738
[0303] c. 182-D1106-057, deposited on October 19, 2005, accession number DSM ACC2739
[0304] d. 182-D1106-058, deposited on October 19, 2005, accession number DSM ACC2740
[0305] e. 182-D1106-059, deposited on October 19, 2005, accession number DSM ACC2741
[0306] f. 182-D1106-062 deposited on October 19, 2005, accession number DSM ACC2742
[0307] g. 182-D1106-067, deposited on October 19, 2005, accession number DSM ACC2743
[0308] h. 182-D758-035, deposited on November 17, 2005, accession number DSM ACC2745
[0309] i. 182-D758-036, deposited on November 17, 2005, accession number DSM ACC2746
[0310] j. 182-D758-040, deposited on November 17, 2005, accession number DSM ACC2747
[0311] k. 182-D1106-061 deposited on November 17, 2005, accession number DSM ACC2748
[0312] l. 182-D1106-279, deposited on October 26, 2006, accession number DSM ACC2808
[0313] m. 182-D1106-294, deposited on October 26, 2006, accession number DSM ACC2809
[0314] n. 182-D1106-362 deposited on October 26, 2006, accession number DSM ACC2810
[0315] A preferred antibody according to the present invention is one that is produced by the hybrid cell described above and is obtainable from the hybrid cell; That is, 37G11 for 182-D1106-055, 37H8 for 182-D1106-056, 38G5 for 182-D1106-057, 38H3 for 182-D1106-058, 39F111 for 182-D1106-059, 43A11 for 182-D1106-062, 61C2 for 182-D1106-067, 26B5 for 182-D758-035, 26D12 for 182-D758-036, 28D10 for 182-D758-040, and 42E12 for 182-D1106-061. 125E1 for 182-D1106-279, 163E12 for 182-D1106-294, and 175D10 for 182-D1106-362; including its chimeric and humanized forms.
[0316] In one embodiment, the antibody having the ability to bind to CLDN18.2 is an antibody selected from the group consisting of (i) an antibody produced by and / or obtainable therefrom a clone deposited under accession number DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810; (ii) an antibody that is a chimeric or humanized form of the antibody in (i); (iii) an antibody having the specificity of the antibody in (i); and (iv) an antibody comprising an antigen-binding portion or an antigen-binding site, particularly a variable region, of the antibody in (i), preferably having the specificity of the antibody in (i).
[0317] Desirable chimeric antibodies and their sequences are shown in the table below.
[0318]
[0319] In a preferred embodiment, the antibody, particularly the chimeric form of the antibody according to the present invention, comprises an antibody comprising a heavy chain constant region (CH) comprising an amino acid sequence derived from a human heavy chain constant region, such as the amino acid sequence represented by SEQ ID NO. 13 or a fragment thereof. In a further preferred embodiment, the antibody, particularly the chimeric form of the antibody according to the present invention, comprises an antibody comprising a light chain constant region (CL) comprising an amino acid sequence derived from a human light chain constant region, such as the amino acid sequence represented by SEQ ID NO. 12 or a fragment thereof. In a particularly preferred embodiment, the antibody, particularly the chimeric form of the antibody according to the present invention, comprises an antibody comprising a CH comprising an amino acid sequence derived from a human CH, such as the amino acid sequence represented by SEQ ID NO. 13 or a fragment thereof, and an antibody comprising a CL comprising an amino acid sequence derived from a human CL, such as the amino acid sequence represented by SEQ ID NO. 12 or a fragment thereof.
[0320] In one embodiment, the antibody having the ability to bind to CLDN18.2 is a chimeric mouse / human IgG1 monoclonal antibody comprising kappa, murine variable light chain, human kappa light chain constant region homologous factor Km (3), murine heavy chain variable region, human IgG1 constant region, homologous factor G1m (3).
[0321] In a specific preferred embodiment, the chimeric form of the antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 14, 15, 16, 17, 18, 19, 51 and a fragment thereof, and / or a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 20, 21, 22, 23, 24, 25, 26, 27, 28 and a fragment thereof.
[0322] In a specific preferred embodiment, the chimeric form of the antibody comprises an antibody comprising a combination of heavy chains and light chains selected from the following possibilities (i) to (ix):
[0323] (i) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 14 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 21 or a fragment thereof, and
[0324] (ii) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 15 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 20 or a fragment thereof, and
[0325] (iii) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 16 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 22 or a fragment thereof, and
[0326] (iv) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 18 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 25 or a fragment thereof, and
[0327] (v) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 17 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 24 or a fragment thereof, and
[0328] (vi) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 19 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 23 or a fragment thereof, and
[0329] (vii) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 19 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 26 or a fragment thereof, and
[0330] (viii) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 19 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 27 or a fragment thereof, and
[0331] (ix) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 19 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 28 or a fragment thereof, and
[0332] (x) The heavy chain comprises the amino acid sequence represented by SEQ ID NO. 51 or a fragment thereof, and the light chain comprises the amino acid sequence represented by SEQ ID NO. 24 or a fragment thereof.
[0333] Antibodies according to (v) or (x) are particularly preferred.
[0334] The "fragment" or "fragment of an amino acid sequence" as used above relates to a part of an antibody sequence, namely a sequence representing an antibody sequence with shortened N and / or C terminals, which, when replacing said antibody sequence in an antibody, maintains the binding of said antibody to CLDN18.2 and preferably maintains the function of said antibody as described herein, e.g., CDC-mediated lysis or ADCC-mediated lysis. Preferably, the fragment of the amino acid sequence comprises at least 80%, preferably at least 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid residues from said amino acid sequence. A fragment of an amino acid sequence selected from the group consisting of sequence numbers 14, 15, 16, 17, 18, 19, 51, 20, 21, 22, 23, 24, 25, 26, 27, and 28 is preferably of the sequence, wherein 17, 18, 19, 20, 21, 22, or 23 amino acids at the N-terminus are removed.
[0335] In a preferred embodiment, an antibody having the ability to bind to CLDN18.2 comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 29, 30, 31, 32, 33, and 34, and a fragment thereof.
[0336] In a preferred embodiment, an antibody having the ability to bind to CLDN18.2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 35, 36, 37, 38, 39, 40, 41, 42, and 43, and a light chain variable region (VL) comprising a fragment thereof.
[0337] In a specific preferred embodiment, an antibody having the ability to bind to CLDN18.2 comprises a combination of a heavy chain variable region (VH) and a light chain variable region (VL) selected from the following possibilities (i) to (ix):
[0338] (i) VH comprises the amino acid sequence represented by SEQ ID NO. 29 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 36 or a fragment thereof, and
[0339] (ii) VH comprises the amino acid sequence represented by SEQ ID NO. 30 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 35 or a fragment thereof, and
[0340] (iii) VH comprises the amino acid sequence represented by SEQ ID NO. 31 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 37 or a fragment thereof, and
[0341] (iv) VH comprises the amino acid sequence represented by SEQ ID NO. 33 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 40 or a fragment thereof, and
[0342] (v) VH comprises the amino acid sequence represented by SEQ ID NO. 32 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 39 or a fragment thereof, and
[0343] (vi) VH comprises the amino acid sequence represented by SEQ ID NO. 34 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 38 or a fragment thereof, and
[0344] (vii) VH comprises the amino acid sequence represented by SEQ ID NO. 34 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 41 or a fragment thereof, and
[0345] (viii) VH comprises the amino acid sequence represented by SEQ ID NO. 34 or a fragment thereof, and VL comprises the amino acid sequence represented by SEQ ID NO. 42 or a fragment thereof, and
[0346] (ix) VH comprises an amino acid sequence represented by SEQ ID NO. 34 or a fragment thereof, and VL comprises an amino acid sequence represented by SEQ ID NO. 43 or a fragment thereof.
[0347] Antibodies according to (v) are particularly desirable.
[0348] According to the present invention, the term “fragment” refers to one or more complementarity determining regions (CDRs), preferably at least one CDR3 variable region, one or more heavy chain variable regions (VHs), and / or one or more light chain variable regions (VLs). In one embodiment, the one or more complementarity determining regions (CDRs) are selected from a set of complementarity determining regions CDR1, CDR2, and CDR3. In a particularly preferred embodiment, the term “fragment” refers to the complementarity determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region (VH) and / or the complementarity determining regions CDR1, CDR2, and CDR3 of the light chain variable region (VL).
[0349] In a preferred embodiment, the antibody having the ability to bind to CLDN18.2 comprises a VH comprising a set of complementary-determining regions CDR1, CDR2, and CDR3 selected from the following embodiments (i) to (vi):
[0350] (i) CDR1: positions 45-52 of sequence number 14, CDR2: positions 70-77 of sequence number 14, CDR3: positions 116-125 of sequence number 14,
[0351] (ii) CDR1: Positions 45-52 of sequence number 15, CDR2: Positions 70-77 of sequence number 15, CDR3: Positions 116-126 of sequence number 15,
[0352] (iii) CDR1: positions 45-52 of sequence number 16, CDR2: positions 70-77 of sequence number 16, CDR3: positions 116-124 of sequence number 16,
[0353] (iv) CDR1: positions 45-52 of sequence number 17, CDR2: positions 70-77 of sequence number 17, CDR3: positions 116-126 of sequence number 17,
[0354] (v) CDR1: positions 44-51 of sequence number 18, CDR2: positions 69-76 of sequence number 18, CDR3: positions 115-125 of sequence number 18, and
[0355] (vi) CDR1 : Positions 45-53 of sequence number 19, CDR2 : Positions 71-78 of sequence number 19, CDR3 : Positions 117-128 of sequence number 19.
[0356] In a preferred embodiment, the antibody having the ability to bind to CLDN18.2 comprises a VL comprising a set of complementary-determining regions CDR1, CDR2, and CDR3 selected from the following embodiments (i) to (ix):
[0357] (i) CDR1: Positions 47-58 of sequence number 20, CDR2: Positions 76-78 of sequence number 20, CDR3: Positions 115-123 of sequence number 20,
[0358] (ii) CDR1: Positions 49-53 of sequence number 21, CDR2: Positions 71-73 of sequence number 21, CDR3: Positions 110-118 of sequence number 21,
[0359] (iii) CDR1: Positions 47-52 of sequence number 22, CDR2: Positions 70-72 of sequence number 22, CDR3: Positions 109-117 of sequence number 22,
[0360] (iv) CDR1: Positions 47-58 of sequence number 23, CDR2: Positions 76-78 of sequence number 23, CDR3: Positions 115-123 of sequence number 23,
[0361] (v) CDR1 : Positions 47-58 of sequence number 24, CDR2 : Positions 76-78 of sequence number 24, CDR3 : Positions 115-123 of sequence number 24,
[0362] (vi) CDR1 : Positions of sequence number 25 47-58, CDR2 : Positions of sequence number 25 76-78, CDR3 : Positions of sequence number 25 115-122,
[0363] (vii) CDR1 : Positions 47-58 of sequence number 26, CDR2 : Positions 76-78 of sequence number 26, CDR3 : Positions 115-123 of sequence number 26,
[0364] (viii) CDR1: positions 47-58 of sequence number 27, CDR2: positions 76-78 of sequence number 27, CDR3: positions 115-123 of sequence number 27 and
[0365] (ix) CDR1 : Positions 47-52 of sequence number 28, CDR2 : Positions 70-72 of sequence number 28, CDR3 : Positions 109-117 of sequence number 28.
[0366] In a preferred embodiment, the antibody having the ability to bind to CLDN18.2 comprises a combination of VH and VL, each comprising a set of complementary-determining regions CDR1, CDR2, and CDR3 selected from the following embodiments (i) to (ix):
[0367] (i) VH : CDR1 : Positions 45-52 of sequence number 14, CDR2 : Positions 70-77 of sequence number 14, CDR3 : Positions 116-125 of sequence number 14, VL : CDR1 : Positions 49-53 of sequence number 21, CDR2 : Positions 71-73 of sequence number 21, CDR3 : Positions 110-118 of sequence number 21,
[0368] (ii) VH : CDR1 : Positions 45-52 of sequence number 15, CDR2 : Positions 70-77 of sequence number 15, CDR3 : Positions 116-126 of sequence number 15, VL : CDR1 : Positions 47-58 of sequence number 20, CDR2 : Positions 76-78 of sequence number 20, CDR3 : Positions 115-123 of sequence number 20,
[0369] (iii) VH : CDR1 : Positions 45-52 of sequence number 16, CDR2 : Positions 70-77 of sequence number 16, CDR3 : Positions 116-124 of sequence number 16, VL : CDR1 : Positions 47-52 of sequence number 22, CDR2 : Positions 70-72 of sequence number 22, CDR3 : Positions 109-117 of sequence number 22,
[0370] (iv) VH : CDR1 : Positions 44-51 of sequence number 18, CDR2 : Positions 69-76 of sequence number 18, CDR3 : Positions 115-125 of sequence number 18, VL : CDR1 : Positions 47-58 of sequence number 25, CDR2 : Positions 76-78 of sequence number 25, CDR3 : Positions 115-122 of sequence number 25,
[0371] (v) VH : CDR1 : Positions 45-52 of sequence number 17, CDR2 : Positions 70-77 of sequence number 17, CDR3 : Positions 116-126 of sequence number 17, VL : CDR1 : Positions 47-58 of sequence number 24, CDR2 : Positions 76-78 of sequence number 24, CDR3 : Positions 115-123 of sequence number 24,
[0372] (vi) VH : CDR1 : Positions 45-53 of sequence number 19, CDR2 : Positions 71-78 of sequence number 19, CDR3 : Positions 117-128 of sequence number 19, VL : CDR1 : Positions 47-58 of sequence number 23, CDR2 : Positions 76-78 of sequence number 23, CDR3 : Positions 115-123 of sequence number 23,
[0373] (vii) VH : CDR1 : positions 45-53 of sequence number 19, CDR2 : positions 71-78 of sequence number 19, CDR3 : positions 117-128 of sequence number 19, VL : CDR1 : positions 47-58 of sequence number 26, CDR2 : positions 76-78 of sequence number 26, CDR3 : positions 115-123 of sequence number 26,
[0374] (viii) VH : CDR1 : positions 45-53 of sequence number 19, CDR2 : positions 71-78 of sequence number 19, CDR3 : positions 117-128 of sequence number 19, VL : CDR1 : positions 47-58 of sequence number 27, CDR2 : positions 76-78 of sequence number 27, CDR3 : positions 115-123 of sequence number 27, and
[0375] (ix) VH : CDR1 : positions 45-53 of sequence number 19, CDR2 : positions 71-78 of sequence number 19, CDR3 : positions 117-128 of sequence number 19, VL : CDR1 : positions 47-52 of sequence number 28, CDR2 : positions 70-72 of sequence number 28, CDR3 : positions 109-117 of sequence number 28.
[0376] In a further preferred embodiment, an antibody having the ability to bind to CLDN18.2 preferably comprises one or more complementary-determining regions (CDRs) of a monoclonal antibody for CLDN18.2, preferably one or more CDR3 variable regions, one or more heavy chain variable regions (VHs), and / or one or more light chain variable regions (VLs) of the monoclonal antibody for CLDN18.2 described herein, and preferably one or more complementary-determining regions (CDRs), preferably one or more CDR3 variable regions, one or more heavy chain variable regions (VHs), and / or one or more light chain variable regions (VLs) described herein. In one embodiment, the one or more complementary-determining regions (CDRs) are selected from the set of complementary-determining regions CDR1, CDR2, and CDR3 described herein. In a particularly preferred embodiment, the antibody having the ability to bind to CLDN18.2 preferably comprises a monoclonal antibody for CLDN18.2, preferably the complementary-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region (VH) of the monoclonal antibody for CLDN18.2 described herein and / or the complementary-determining regions CDR1, CDR2, and CDR3 of the light chain variable region (VL), and preferably comprises the complementary-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region (VH) and / or the complementary-determining regions CDR1, CDR2, and CDR3 of the light chain variable region (VL) described herein.
[0377] In one embodiment, an antibody comprising one or more CDRs, sets of CDRs, or combinations of sets of CDRs as described herein comprises said CDRs together with a framework region between them. Preferably, the portion will also comprise at least about 50% of either or both of the first and fourth framework regions, and the 50% is 50% of the C-terminus of the first framework region and 50% of the N-terminus of the fourth framework region. The construction of an antibody produced by recombinant DNA technology may involve introducing a residue N-terminus or C-terminus into a variable region encoded by a linker introduced to facilitate cloning or other manipulation steps, and may include the introduction of a linker that combines the variable region of the present invention with an additional protein sequence comprising an immunoglobulin heavy chain, another variable domain (e.g., in the production of a diabody), or a protein label.
[0378] In one embodiment, an antibody comprising one or more CDRs, sets of CDRs, or combinations of sets of CDRs as described herein comprises said CDRs in a human antibody framework.
[0379] In the present invention, regarding the heavy chain of an antibody, an antibody comprising a specific chain, or a specific region or sequence preferably relates to a situation where all heavy chains of said antibody comprise said specific chain, region, or sequence. This applies correspondingly to the light chain of the antibody.
[0380] It should be understood that the antibodies described herein may be delivered to a patient by administering a nucleic acid, such as RNA encoding the antibody, and / or by administering a host cell containing a nucleic acid, such as RNA encoding the antibody. Accordingly, when administered to a patient, the nucleic acid encoding the antibody may be present in a naked form, in the form of a suitable delivery carrier, such as a liposome or viral particle, or within a host cell. The provided nucleic acid can produce antibodies over a long period in a consistent manner that mitigates at least partially observed instability for therapeutic antibodies. The nucleic acid delivered to the patient may be produced by recombinant means. If the nucleic acid is administered to the patient without being present within a host cell, it is desirable that it be absorbed by the patient's cell for the expression of the antibody encoded by the nucleic acid. If the nucleic acid is administered to the patient while present within a host cell, it is desirable that the nucleic acid be expressed by the host cell within the patient to produce the antibody encoded by the nucleic acid.
[0381] As used herein, the term “nucleic acid” is intended to include DNA and RNA, such as genomic DNA, cDNA, mRNA, recombinantly produced molecules, and chemically synthesized molecules. Nucleic acids may be single-stranded or double-stranded. RNA includes in vitro transcribed RNA (IVT RNA) or synthetic RNA.
[0382] Nucleic acids may be included in a vector. As used herein, the term “vector” includes any vector known to those skilled in the art, including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as adenovirus vectors or baculovirus vectors, or artificial chromosome vectors such as bacterial artificial chromosome (BAC), yeast artificial chromosome (YAC), or P1 artificial chromosome (PAC). The vector includes cloning vectors as well as expression vectors. Expression vectors include plasmids as well as viral vectors and generally contain a desired coding sequence and a suitable DNA sequence required for the expression of the coding sequence operably linked to a specific host organism (e.g., bacteria, yeast, plants, insects, or mammals) or in vitro expression system. Cloning vectors are generally used to manipulate and amplify a desired DNA fragment and may lack the functional sequence required for the expression of the desired DNA fragment.
[0383] In the context of the present invention, the term “RNA” relates to a molecule comprising ribonucleotide residues, preferably a molecule composed entirely or largely of ribonucleotide residues. “Ribonucleotide” relates to a nucleotide having a hydroxyl group at the 2’-position of a β-D-ribofuranosyl group. The term includes double-stranded RNA, single-stranded RNA, isolated RNA, e.g., partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as RNA modified from naturally occurring RNA by the addition, deletion, substitution, and / or alteration of one or more nucleotides. Such alterations may include, for example, adding non-nucleotide material to one or more nucleotides of the RNA, or internally to the end(s) of the RNA. Additionally, the nucleotides of the RNA molecule may include non-standard nucleotides, e.g., non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These modified RNAs may be referred to as analogs or analogs of naturally occurring RNA.
[0384] According to the present invention, the term “RNA” includes, preferably relates to, “mRNA” meaning “messenger RNA,” and relates to a “transcript” that can be produced using DNA as a template and encodes a peptide or protein. mRNA typically comprises a 5’ untranslated region (5’-UTR), a protein or peptide coding region, and a 3’ untranslated region (3’-UTR). mRNA has a limited half-life in cells and in vitro. Preferably, mRNA is produced by in vitro transcription using a DNA template. In one embodiment of the present invention, RNA is obtained by in vitro transcription or chemical synthesis. Methodologies for in vitro transcription are known to those skilled in the art. For example, various commercially available in vitro transcription kits exist.
[0385] In order to increase the expression and / or stability of the RNA used according to the present invention, the expressed peptide or protein may preferably be modified without changing its sequence.
[0386] In the context used according to the present invention, the term “modification” of RNA includes any modification of RNA that is not naturally present in said RNA. Such modified RNA is included herein by the term “RNA”.
[0387] For example, RNA according to the present invention may modify naturally occurring or synthetic ribonucleotides to increase its stability and / or reduce cytotoxicity. For example, in one embodiment, 5-methylcytidine in the RNA used according to the present invention is partially or entirely replaced with cytidine, preferably entirely replaced with cytidine. Alternatively or additionally, in one embodiment, pseudouridine in the RNA used according to the present invention is partially or entirely replaced with uridine, preferably entirely replaced with uridine.
[0388] In one embodiment, the term “modification” relates to providing a 5’-cap or a 5’-cap analog to RNA. The term “5’-cap” refers to a cap structure found at the 5’-terminus of an mRNA molecule and consists of a guanosine nucleotide connected to the mRNA via a generally uncommon 5’-to-5’ triphosphate bond. In one embodiment, this guanosine is methylated at the 7’-position. The term “conventional 5’-cap” refers to a naturally occurring RNA 5’-cap, preferably a 7-methylguanosine cap (m7G). In the context of the invention, the term “5’-cap” comprises a 5’-cap analog similar to the RNA cap structure and is preferably modified to have the ability to stabilize RNA when attached thereto in vivo and / or within a cell.
[0389] Preferably, when RNA is delivered to a cell, particularly a cell present in vivo, that is, transfected, the RNA expresses the protein or peptide it encodes.
[0390] The term "transfusion" relates to the introduction of nucleic acids, particularly RNA, into a cell. Furthermore, for the purposes of the present invention, the term "transfusion" includes the introduction of nucleic acids into a cell or the uptake of nucleic acids by such cell, wherein the cell may be present in a subject, e.g., a patient. Accordingly, according to the present invention, the cell for the transfusion of nucleic acids described herein is In vitro Alternatively, it may exist in vivo, and, for example, the cell may form part of a patient's organ, tissue, and / or organism. According to the present invention, transfection may be transient or stable. In some cases where transfection is applied, it is sufficient for the transfected genetic material to be expressed only transiently. Since the nucleic acid introduced during the transfection process generally does not bind to the nuclear genome, the foreign nucleic acid is diluted or degraded through mitosis. Cells that allow episomal amplification of nucleic acid significantly reduce the rate of dilution. If it is desirable for the transfected nucleic acid to actually remain in the genome of the cell and its daughter cells, stable transfection must occur. RNA may be transfected into a cell to transiently express its encoded protein.
[0391] The term "stability" of RNA refers to the "half-life" of RNA. "Half-life" refers to the time required to remove half of the activity, amount, or number of a molecule. In the context of the present invention, the half-life of RNA indicates the stability of said RNA. The half-life of RNA may affect the "duration of expression" of RNA. RNA with a long half-life may be expected to be expressed over a long period of time.
[0392] In the context of the present invention, the term "transcription" relates to the process in which a genetic code within a DNA sequence is transcribed into RNA. Subsequently, the RNA can be translated into a protein. According to the present invention, the term "transcription" refers to " In vitro Includes "transcribed", where the term " In vitro "Transcription" refers to RNA, particularly mRNA, obtained in a cell-free system, preferably using a suitable cell extract. In vitro This relates to a process of synthesis. Preferably, a cloning vector is applied for the generation of a transcript. These cloning vectors are generally referred to as transcript vectors and are included in the term "vector" according to the present invention.
[0393] According to the present invention, the term "translation" relates to a process in a cell's ribosome in which a strand of messenger RNA induces the assembly of a sequence of amino acids to produce a peptide or protein.
[0394] The term "expression" is used in the most general sense according to the present invention and includes, for example, the production of RNA and / or peptides or proteins by transcription and / or translation. With respect to RNA, the terms "expression" or "translation" relate particularly to the production of peptides or proteins. Additionally, it includes the partial expression of nucleic acids. Furthermore, expression may be transient or stable. According to the present invention, the term expression also includes "abnormal expression" or "abnormal expression."
[0395] "Abnormal expression" or "abnormal expression" according to the present invention means that expression is altered, preferably increased, compared to a standard, in a subject without disease, for example, due to abnormal expression or abnormal expression of a specific protein, for example, a tumor antigen. An increase in expression means an increase of at least 10%, particularly at least 20%, at least 50%, or at least 100%. In one embodiment, the expression is found only in diseased tissue, whereas expression in healthy tissue is suppressed.
[0396] The term “specifically expressed” means that a protein is essentially expressed only in a specific tissue or organ. For example, a tumor antigen specifically expressed in the gastric mucosa means that the protein is primarily expressed in the gastric mucosa and is not expressed in other tissues or is not expressed to a significant degree in other tissue or organ types. Thus, a protein that is expressed exclusively in the cells of the gastric mucosa and to a significantly low degree in any other tissue, such as the testis, is specifically expressed in the cells of the gastric mucosa. In some embodiments, the tumor antigen may also be specifically expressed under normal conditions in one or more tissue types or organs, such as in two or three tissue types or organs, but preferably not exceeding three other tissue or organ types. In this case, the tumor antigen is specifically expressed in these organs. For example, if the tumor antigen is preferably expressed to approximately equal degrees in the lungs and stomach under normal conditions, said tumor antigen is specifically expressed in the lungs and stomach.
[0397] According to the present invention, the term "RNA encoding" means that when RNA is present in a suitable environment, preferably within a cell, RNA can encode and produce a protein or peptide.
[0398] Some aspects of the present invention are nucleic acids, such as RNA encoding the antibody described herein. In vitro Transfect and preferably from a low precursor frequency to a clinically valid cell number In vitro It relies on the protonation of host cells that are amplified and then delivered to a recipient such as a patient. According to the present invention, the host cells used for treatment may be autologous, allogeneic, or syngeneic with respect to the treated recipient.
[0399] The term "autologous" is used to describe anything derived from the same source. For example, "autologous transplantation" refers to the transplantation of tissue or organs derived from the same source. This procedure is advantageous because it overcomes the immune barrier that would otherwise cause a rejection reaction.
[0400] The term "homologous" is used to describe origins from different individuals of the same species. Two or more individuals are said to be homologous to each other when their genes at one or more loci are not identical.
[0401] The term "synonymy" is used to describe individuals or tissues having the same genotype, that is, identical twins or animals or tissues derived from the same synonymy lineage.
[0402] The term "xenogeneic" is used to describe something composed of various different elements. For example, transferring bone marrow from one individual to another constitutes a xenotransplant. Xenogeneic genes are genes derived from a source other than the subject.
[0403] The term "peptide" according to the present invention refers to a substance comprising oligopeptides and polypeptides, comprising two or more, preferably three or more, preferably four or more, preferably six or more, preferably eight or more, preferably nine or more, preferably ten or more, preferably thirteen or more, preferably six or more, preferably twenty-one or more, more preferably eight, ten, twenty, thirty, forty, or fifty or fewer, particularly one or fewer than one hundred amino acids covalently bonded by peptide bonds. The term "protein" refers to a large peptide, preferably a peptide having more than one hundred amino acid residues, but generally the terms "peptide" and "protein" are synonyms and are used interchangeably herein.
[0404] The teaching of the present invention regarding specific amino acid sequences, e.g., amino acid sequences shown in the sequence list, should be understood as relating to variants of said specific sequences that give rise to sequences functionally equivalent to said specific sequences, e.g., amino acid sequences having the same or similar characteristics as said specific amino acid sequences.
[0405] One important characteristic is to maintain binding to the antibody's target or to maintain the antibody's effector function. Preferably, a sequence that is a variant of a specific sequence maintains binding to the antibody's target when replacing the specific sequence within the antibody, and preferably maintains the antibody's function, e.g., CDC-mediated lysis or ADCC-mediated lysis, as described herein.
[0406] In particular, those skilled in the art will understand that the sequences of the CDR region, the hypervariable region, and the variable region may be modified without losing the ability of the antibody to bind to its target. For example, the CDR region may be identical to or highly homologous to the region of the antibody specified herein. “Highly homologous” is intended to mean that there may be 1 to 5, preferably 1 to 4, substitutions within the CDR, such as 1 to 3 or 1 or 2. Additionally, the hypervariable region and the variable region may be modified to exhibit substantial homology to the region of the antibody specifically disclosed herein.
[0407] The term “variant” according to the present invention refers particularly to mutants, splice variants, stereotypes, isoforms, allelic variants, species variants, and species homologs, particularly those that exist naturally. Allelic variants relate to changes in the normal sequence of a gene, and their significance is often unclear. Complete gene sequencing often identifies numerous allelic variants for a given gene. Species homologs are nucleic acid or amino acid sequences of a different species origin from a given nucleic acid or amino acid sequence. The term “variant” may include all variants and stereotype variants that have been modified after translation.
[0408] For the purposes of the present invention, "variants" of an amino acid sequence include amino acid insertion variants, amino acid addition variants, amino acid deletion variants, and / or amino acid substitution variants. Additionally, amino acid deletion variants comprising deletions at the N-terminus and / or C-terminus of a protein are also referred to as N-terminus and / or C-terminus truncated variants.
[0409] Amino acid insertion variants involve the insertion of a single or more amino acids in a specific amino acid sequence. In the case of amino acid sequence variants with insertions, one or more amino acid residues are inserted into specific sites of the amino acid sequence, but random insertion is also possible through appropriate screening of the resulting product.
[0410] The amino acid addition variant comprises one or more amino acids, for example, an amino-terminal and / or carboxy-terminal fusion of 1, 2, 3, 5, 10, 20, 30, or 50 or more amino acids.
[0411] Amino acid deletion variants are characterized by removing one or more amino acids from a sequence, for example, removing 1, 2, 3, 5, 10, 20, 30, or 50 or more amino acids. The deletion may be at any position in the protein.
[0412] Amino acid substitution variants are characterized by the removal of at least one residue from the sequence and the insertion of another residue in its place. Modifications at positions in amino acid sequences that are not conserved between homologous proteins or peptides and / or modifications that replace an amino acid with another amino acid having similar characteristics are preferred. Preferably, amino acid changes in protein variants are conserved amino acid changes, that is, substitutions of similarly charged or uncharged amino acids. Conserved amino acid changes include substitutions to one of the amino acid families associated with their side chains. Naturally occurring amino acids are generally divided into four families: acidic amino acids (aspartate, glutamate), basic amino acids (lysine, arginine, histidine), nonpolar amino acids (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar amino acids (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine, tryptophan, and tyrosine are sometimes also classified as aromatic amino acids.
[0413] Preferably, the degree of similarity, preferably the identity between a given amino acid sequence and an amino acid sequence that is a variant of the given amino acid sequence, will be at least about 60%, 65%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of similarity or identity is preferably implied to an amino acid region that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the total length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably given for about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, preferably consecutive amino acids. In a preferred embodiment, the degree of similarity or identity is given for the entire length of the reference amino acid sequence. Alignment for determining sequence similarity, preferably sequence identity, can be performed using tools known in the art, preferably using the best sequence alignment, for example, using Align, using standard settings, preferably using EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0414] "Sequence similarity" represents the percentage of amino acids exhibiting identical or conservative amino acid substitutions. "Sequence identity" between two amino acid sequences represents the percentage of identical amino acids between the sequences.
[0415] The term "percentage identity" refers to the percentage of identical amino acid residues between two sequences to be compared obtained after optimal alignment; this percentage is purely statistical, and the differences between the two sequences are distributed randomly and over their entire lengths. Sequence comparison between two amino acid sequences is typically performed by comparing them after optimal alignment, and this comparison is carried out by segments or "comparison windows" to identify and compare local regions of sequence similarity. Optimal alignment of sequences for comparison is performed, in addition to manual alignment, by the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482; by the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443; and by Pearson and Lipman, 1988, Proc. Natl Acad. Sci. Similarity search methods of USA 85, 2444 or these algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.) may be generated by computer programs using these algorithms.
[0416] Percentage identity is calculated by determining the number of identical positions between two sequences to be compared, dividing this number by the number of positions compared, and multiplying the result by 100 to obtain the percentage identity between the two sequences.
[0417] The terms “cell” or “host cell” preferably relate to an intact cell, that is, a cell having an intact membrane that does not release normal intracellular components such as enzymes, organelles, or genetic material. An intact cell is preferably a live cell, that is, a live cell capable of performing normal metabolic functions. Preferably, the terms relate to any cell that can be transfected with exogenous nucleic acid according to the present invention. Preferably, a cell transfected with exogenous nucleic acid can express nucleic acid. Preferably, when transfected with exogenous nucleic acid and delivered to a recipient, the cell can express nucleic acid in the recipient. The term “cell” includes bacterial cells; other useful cells are yeast cells, fungal cells, or mammalian cells. Suitable bacterial cells include cells from Gram-negative bacterial strains, such as strains of Escherichia coli, Proteus, and Pseudomonas, and Gram-positive bacterial strains, such as strains of Bacillus, Streptomyces, Staphylococcus, and Lactococcus. Suitable fungal cells include cells from species of Trichoderma, Neurospora, and Aspergillus. Suitable yeast cells include cells from species of Saccharomyces (e.g., Saccharomyces cerevisiae), Schizosaccharomyces (e.g., Schizosaccharomyces pombe), Pichia (e.g., Pichia pastoris and Pichia methanolicd), and Hansenula. Suitable mammalian cells include, for example, CHO cells, BHK cells, HeLa cells, COS cells, and 293 HEK cells. However, amphibian cells, insect cells, plant cells, and any other cells used in the art for the expression of heterologous proteins may also be used.Mammalian cells, such as those from humans, mice, hamsters, pigs, goats, and primates, are particularly desirable for protonation. These cells can be derived from various tissue types and include primary cells and cell lines, such as immune system cells, particularly antigen-presenting cells, such as dendritic cells and T cells, stem cells such as hematopoietic stem cells and mesenchymal stem cells, and other cell types. Antigen-presenting cells are cells that display antigens on their surface in terms of major histocompatibility complexes. T cells can recognize these complexes using their T cell receptors (TCRs).
[0418] The term “transgenic animal” refers to an animal having a genome containing one or more transplant genes, preferably heavy chain and / or light chain transplant genes, or transplant chromosomes (whether or not incorporated into the animal’s natural genomic DNA), preferably capable of expressing the transplant genes. For example, a transgenic mouse may have human light chain transplant genes and human heavy chain transplant genes or human heavy chain transplant chromosomes so that the mouse produces human anti-tumor antigen antibodies when immunized with tumor antigens and / or cells expressing tumor antigens. The human heavy chain transplant gene may be incorporated into the chromosomal DNA of the mouse, as in the case of the transgenic mouse, e.g., the HCo7 or HCo2 mouse, or the human heavy chain transplant gene may be maintained extrachromosomes, as in the case of the transgenic mouse (e.g., KM) as described in WO 02 / 43478. These genetically and chromosomal transplanted mice can generate multiple homologs of human monoclonal antibodies against tumor antigens (e.g., IgG, IgA, and / or IgE) by performing VDJ recombination and homologous switching.
[0419] As used herein, “reduction,” “reduction,” or “inhibition” means the ability to reduce, at a level, the expression level or the level of cell proliferation, the overall reduction or, preferably, at least 5%, at least 10%, at least 20%, more preferably at least 50%, and most preferably at least 75%.
[0420] Terms such as “increase” or “enhancement” relate to an increase or enhancement of preferably at least about 10%, preferably at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 80%, and most preferably at least 100%, at least 200%, at least 500%, at least 1000%, or at least 10000% or more.
[0421] The antibodies described herein may be produced by various techniques, including conventional monoclonal antibody methodologies, such as the standard somatic hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). While somatic hybridization procedures are preferred in principle, other techniques for producing monoclonal antibodies may be used, such as viral or oncogenic transformation of B-lymphocytes or phage display techniques using a library of antibody genes.
[0422] The preferred animal system for producing hybrid cells that secrete monoclonal antibodies is the murine system. The generation of hybrid cells in mice is a very well-established procedure. Immunization protocols and techniques for isolating immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.
[0423] Other preferred animal systems for producing hybrid cells secreting monoclonal antibodies are rat and rabbit systems (e.g., as described in Spieker-Polet et al., Proc. Natl. Acad. Sci. USA 92:9348 (1995), and also see Rossi et al., Am. J. Clin. Pathol. 124: 295 (2005)).
[0424] In another preferred embodiment, human monoclonal antibodies may be produced using genetically modified or chromosomal modified mice that possess a part of the human immune system rather than a mouse system. These genetically modified and chromosomal modified mice include mice known as HuMAb mice and KM mice, respectively, collectively referred to herein as “genetically modified mice.” Production of human antibodies in these genetically modified mice may be carried out as described in detail for CD20 in WO2004-035607.
[0425] Another strategy for generating monoclonal antibodies is to directly isolate the gene encoding the antibody from lymphocytes that produce antibodies of a defined specificity, for example, see Babcock et al., 1996, and a novel strategy for generating monoclonal antibodies from a single, isolated lymphocyte that produces antibodies of a defined specificity. For more information on recombinant antibody engineering, see the literature [Welschof and Kraus, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8 and Benny KC Lo Antibody Engineering ISBN 1-58829-092-1.].
[0426] To generate antibodies, mice may be immunized as described by a carrier-conjugated peptide derived from an antigen sequence, i.e., a sequence that may be for an antibody, a concentrated product of a recombinantly expressed antigen or a fragment thereof, and / or cells expressing the antigen. Alternatively, mice may be immunized with DNA encoding the antigen or a fragment thereof. Furthermore, if immunization using a purified or concentrated antigen product does not induce antibodies, mice may be immunized with antigen-expressing cells, e.g., a cell line, to promote an immune response.
[0427] The immune response can be monitored through an immune protocol using plasma and serum samples obtained from tail vein or retroorbital hemorrhage. Mice with sufficient immunoglobulin titers can be used for fusion. To increase the proportion of specific antibody-secreting hybrid cells, mice can be sacrificed and, three days prior to spleen removal, can be augmented with antigen-expressing cells intraperitoneally or intravenously.
[0428] To generate hybrid cells that produce monoclonal antibodies, splenocytes and lymph node cells from immunized mice can be isolated and fused to a suitable immortalized cell line, such as a mouse myeloma cell line. Subsequently, the obtained hybrid cells can be screened for the production of antigen-specific antibodies. Afterward, individual wells can be screened for antibody-secreting hybrid cells by ELISA. Antigen-specific antibodies can be identified through immunofluorescence and FACS analysis using antigen-expressing cells. Antibody-secreting hybrid cells can be transferred and re-screened, and if they remain positive for monoclonal antibodies, they can be subcloned by limiting dilution. Stable subclones can be cultured in vitro to generate antibodies in tissue culture medium for characterization.
[0429] In addition, antibodies can be produced in host cell-transfected cells using, for example, a combination of recombinant DNA technology and gene transduction methods well known in the art (Morrison, S. (1985) Science 229: 1202).
[0430] For example, in one embodiment, the gene(s) of interest, e.g., the antibody gene, may be ligated into an expression vector, such as an expression plasmid for eukaryotes, as used by the GS gene expression system disclosed in WO 87 / 04462, WO 89 / 01036, and EP 338 841, or other expression systems known in the art. The purified plasmid having the cloned antibody gene may be introduced into a eukaryotic host cell, such as a CHO cell, NS / 0 cell, HEK293T cell, or HEK293 cell, or alternatively into other eukaryotic cells such as plant-derived cells, fungal or yeast cells. The method used to introduce these genes may be a method described in the art, such as electroporation, lipofectine, or lipofectamine. After these antibody genes are introduced into the host cell, the cell expressing the antibody may be identified and selected. These cells represent transfected cells capable of producing antibodies by amplifying and upscaling their expression levels. Recombinant antibodies can be isolated and purified from these culture supernatants and / or cells.
[0431] Alternatively, the cloned antibody gene may be expressed in other expression systems, including prokaryotic cells, e.g., microorganisms, e.g., E. coli. Additionally, the antibody may be produced in milk from sheep and rabbits, eggs from hens, or genetically modified non-human animals such as genetically modified plants, see, for example, Verma, R., et al. (1998) J. Immunol. Meth. 216: 165-181; Pollock, et al. (1999) J. Immunol. Meth. 231: 147-157; and Fischer, R., et al. (1999) Biol. Chem. 380: 825-839.
[0432] Chimera
[0433] Murine antibodies exhibit high immunogenicity in humans upon repeated application, leading to a decrease in therapeutic efficacy. Major immunogenicity is mediated by the heavy chain constant region. The immunogenicity of murine antibodies in humans can be reduced or completely avoided if the respective antibodies are chimeric or humanized. Chimeric antibodies are antibodies having different parts derived from different animal species, such as murine antibodies and antibodies having variable regions derived from human immunoglobulin constant regions. Antibody chimericization is achieved by combining the variable regions of the murine antibody heavy and light chains with the constant regions of the human heavy and light chains (e.g., described in the literature [Kraus et al., in Methods in Molecular Biology series, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8]). In a preferred embodiment, the chimeric antibody is produced by combining the human kappa-light chain constant region with the murine light chain variable region. In addition, in a preferred embodiment, a chimeric antibody can be produced by conjugating a human lambda-light chain constant region to a murine light chain variable region. Preferred heavy chain constant regions for producing a chimeric antibody are IgG1, IgG3, and IgG4. Other preferred heavy chain constant regions for producing a chimeric antibody are IgG2, IgA, IgD, and IgM.
[0434] humanization
[0435] Antibodies primarily interact with target antigens through amino acid residues located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, amino acid sequences within the CDR exhibit greater variability among individual antibodies than sequences outside the CDR. Since CDR sequences are involved in most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of naturally occurring specific antibodies by constructing an expression vector containing CDR sequences from naturally occurring specific antibodies that are grafted onto the framework sequence from other antibodies of different properties (see, for example, the literature [Riechmann, L. et al. (1998) Nature 332: 323-327; Jones, P. et al. (1986) Nature 321: 522-525; and Queen, C. et al. (1989) Proc. Natl. Acad. Sci. USA 86: 10029-10033]). These framework sequences can be obtained from public DNA databases containing germline antibody gene sequences. Since these germline sequences do not contain fully assembled variable genes formed by V(D)J binding during B cell maturation, they will differ from mature antibody gene sequences. Germline gene sequences will also differ from the sequences of secondary repertoire antibodies that are uniformly highly affinity across the entire variable region.
[0436] The ability of an antibody to bind to an antigen can be determined using standard binding assays (e.g., ELISA, Western blot, immunofluorescence, and flow cytometry).
[0437] To purify the antibody, selected hybrid cells can be grown in a 2-liter spinner flask for monoclonal antibody purification. Alternatively, the antibody can be produced in a dialysis-based bioreactor. The supernatant can be filtered and, if necessary, concentrated prior to affinity chromatography using protein G-cephalosporose or protein A-cephalosporose. The eluted IgG can be examined by gel electrophoresis and high-performance liquid chromatography to ensure purity. The buffer solution can be exchanged within PBS, and the concentration can be determined by OD280 using an extinction coefficient of 1.43. The monoclonal antibody can be dispensed and stored at -80°C.
[0438] To determine whether a selected monoclonal antibody binds to a specific epitope, site-specific or multi-site-specific mutagenesis may be used.
[0439] To determine the isotype of the antibody, an isotype ELISA can be performed using various commercially available kits (e.g., Zymed, Roche Diagnostics). Wells of the microquantification plate can be coated with anti-mouse Ig. After blocking, the plate is incubated with a monoclonal antibody or a purified isotype control at ambient temperature for 2 hours. Subsequently, wells can be reacted with mouse IgG1, IgG2a, IgG2b, or IgG3, IgA, or mouse IgM-specific peroxidase-conjugated probes. After washing, the plate can be developed with ABTS substrate (1 mg / ml) and analyzed at an OD of 405–650. Alternatively, the IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche, Cat. No. 1493027) can be used as per the manufacturer's instructions.
[0440] Flow cytometry may be used to verify the presence of antibodies in the serum of immunized mice or the binding of monoclonal antibodies to live cells expressing an antigen. Naturally expressing cell lines, cell lines expressing the antigen after transfection, and cell lines expressing negative controls lacking antigen expression (grown under standard growth conditions) may be mixed with various concentrations of monoclonal antibodies in mixed cell supernatant or PBS containing 1% FBS and incubated at 4°C for 30 minutes. After washing, APC- or Alexa647-labeled anti-IgG antibodies may bind to antigen-bound monoclonal antibodies under the same conditions as primary antibody staining. Samples may be analyzed by flow cytometry using a FACS instrument that utilizes light and side scattering properties as gates on single live cells. To distinguish antigen-specific monoclonal antibodies from non-specific binders in a single measurement, the method of co-transfection may be employed. Cells transiently transfected with an antigen-encoding plasmid and a fluorescent marker can be stained as described above. Transfected cells can be detected in fluorescent channels different from those of cells stained with antibodies. Since most transfected cells express both transplant genes, antigen-specific monoclonal antibodies bind preferentially to cells expressing the fluorescent marker, whereas non-specific antibodies bind to non-transfected cells in comparable proportions. Alternative assays using fluorescence microscopy can be used in addition to or instead of flow cytometry. Cells can be accurately stained as described above and examined with a fluorescence microscope.
[0441] Immunofluorescence microscopy analysis may be used to demonstrate the presence of antibodies in the serum of immunized mice or the binding of monoclonal antibodies to live cells expressing the antigen. For example, cell lines expressing spontaneously or after antigen transduction and negative controls lacking antigen expression are grown on chamber slides under standard growth conditions in DMEM / F12 medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU / mL penicillin, and 100 µg / mL streptomycin. Subsequently, the cells may be fixed with methanol or paraformaldehyde or left untreated. Next, the cells may be reacted with a monoclonal antibody against the antigen at 25°C for 30 minutes. After washing, the cells may be reacted with Alexa555-labeled anti-mouse IgG secondary antibodies (Molecular Probes) under the same conditions. Subsequently, the cells may be examined by fluorescence microscopy.
[0442] Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis can be performed by preparing cell extracts from antigen-expressing cells and appropriate negative controls. After electrophoresis, the separated antigens are transferred to a nitrocellulose membrane and probed with a monoclonal antibody to be blocked and tested. IgG binding can be detected using anti-mouse IgG peroxidase and can be developed onto an ECL substrate.
[0443] Antibodies may be further tested for reactivity with antigens by immunohistochemistry in a manner well known to those skilled in the art, for example, using non-cancer or cancer tissue samples obtained from mice carrying xenografted tumors, obtained from patients during routine surgical procedures, spontaneously, or incubated with cell lines expressing the antigen after transfection, or paraffin-embedded tissue sections fixed with paraformaldehyde or acetone. For immunostaining, antibodies reacting with the antigen may be incubated, and then horseradish-peroxidase-conjugated goat anti-mouse or goat anti-rabbit antibodies (DAKO) may be produced according to the supplier's instructions.
[0444] Antibodies can be used to test their ability to mediate the phagocytosis and killing of cells expressing tumor antigens. Testing the activity of monoclonal antibodies in vitro will provide initial screening before testing in vivo models.
[0445] Antibody-dependent cell-mediated cytotoxicity (ADCC)
[0446] Briefly, polymorphonuclear cells (PMNs), NK cells, monocytes, mononuclear cells, or other effector cells from a healthy donor can be purified by Ficoll Hypaque density centrifugation and then purified by lysis of contaminating red blood cells. The washed effector cells are suspended in RPMI supplemented with 10% heat-inactivated fetal calf serum or 5% heat-inactivated human serum, and tumor antigens are expressed at various ratios of effector cells to target cells 51It can be mixed with Cr-labeled target cells. Alternatively, the target cells can be labeled with a fluorescence-enhancing ligand (BATDA). The fluorescent chelation of high-grade Europium with the enhancing ligand released from dead cells can be measured using a fluorescence detector. Another alternative technique involves transfecting target cells with luciferase. Subsequently, the added Lucifer Yellow can be oxidized only by live cells. Then, purified anti-tumor antigen IgG can be added at various concentrations. Irrelevant human IgG can be used as a negative control. The assay can be performed at 37°C for 4 to 20 hours, depending on the type of effector cells used. The sample 51 Cell lysis can be analyzed by measuring Cr release or the presence of EuTDA chelate in the culture supernatant. Alternatively, live cells can be measured by luminescence resulting from the oxidation of Lucifer Yellow.
[0447] In addition, anti-tumor antigen monoclonal antibodies can be tested in various combinations to determine whether cell lysis is enhanced by multiple monoclonal antibodies.
[0448] Complement-dependent cytotoxicity (CDC)
[0449] Monoclonal anti-tumor antigen antibodies can be tested for their ability to mediate CDC using various known techniques. For example, serum for complement can be obtained from blood in a manner known to those skilled in the art. Other methods may be used to determine the CDC activity of mAbs. 51 Cr release can be measured, for example, or increased membrane permeability can be evaluated using the propidium iodide (PI) exclusion method. Briefly, target cells are washed and 5 x 10 5 / ml can be incubated at various concentrations of mAb at room temperature or 37°C for 10–30 minutes. Subsequently, serum or plasma was added to a final concentration of 20% (v / v), and the cells were incubated at 37°C for 20–30 minutes. All cells of each sample can be added to the PI solution in a FACS tube. Then, the mixture can be analyzed immediately using flow cytometry analysis with a FACSArray.
[0450] In general analysis, CDC induction can be determined in adherent cells. In one embodiment of this analysis, cells were placed in a tissue-culture flat-bottom microquantification plate at a density of 3 x 10⁶ 4 Inoculate 24 hours prior to analysis at well density. The next day, remove the growth medium and incubate the cells with antibodies three times. Control cells are incubated with growth medium or growth medium containing 0.2% saponin, respectively, to measure background lysis and maximum lysis. After 20 minutes of incubation, remove the supernatant at room temperature, add 20% (v / v) human plasma or serum to the cells in DMEM (preheated to 37°C), and incubate for another 20 minutes at 37°C. Add all cells of each sample to a propidium iodide solution (10 µg / ml). Then, replace the supernatant with PBS containing 2.5 µg / ml ethidium bromide, and measure the fluorescence emission at 600 nm upon excitation at 520 nm using a Tecan Safire. The specific lysis percentage is calculated as follows: Specific lysis % = (Fluorescent sample - Fluorescent background) / (Fluorescent maximum lysis - Fluorescent background) x 100
[0451] Induction of programmed cell death and inhibition of cell proliferation by monoclonal antibodies
[0452] To test the ability to initiate programmed cell death, monoclonal anti-tumor antigen antibodies can be incubated, for example, with tumor antigen-positive tumor cells or tumor antigen-transfected tumor cells at 37°C for about 20 hours. Cells can be harvested, washed in Annexin-V binding buffer (BD Biosciences), and incubated for 15 minutes with Annexin V conjugated with FITC or APC (BD Biosciences). All cells of each sample can be added to PI solution (10 µg / ml in PBS) in FACS tubes and evaluated immediately by flow cytometry (as above). Alternatively, general inhibition of cell proliferation by monoclonal antibodies can be detected using a commercially available kit. The DELFIA cell proliferation kit (Perkin-Elmer, Cat. No. AD0200) is a non-radioisotope immunoassay based on measuring the content of 5-bromo-2'-deoxyuridine (BrdU) during DNA synthesis in cells proliferating in microplates. The contained BrdU is detected using a europium-labeled monoclonal antibody. To enable antibody detection, cells are fixed using a fixation solution and DNA is denatured. The unbound antibody is washed, and a DELFIA inducer is added to dissociate europium ions from the labeled antibody in solution, thereby forming a high-fluorescence chelate with the components of the DELFIA inducer. The fluorescence measured using fluorescence quantification, which degrades over time during detection, is proportional to the DNA synthesis in the cells of each well.
[0453] preclinical research
[0454] The antibodies described herein can also be tested in in vivo models (e.g., in immunodeficient mice harboring xenografted tumors incubated with cell lines expressing tumor antigens to determine their efficacy in controlling the growth of tumor cells expressing tumor antigens).
[0455] In vivo studies following xenografting of tumor antigen-expressing tumor cells into immunocompromised mice or other animals may be performed using the antibodies described herein. Antibodies can be administered to tumor-free mice via injection of tumor cells to measure the effect of the antibody in preventing tumor formation or tumor-related symptoms. By administering antibodies to tumor-carrying mice, the therapeutic efficacy of each antibody in reducing tumor growth, metastasis, or tumor-related symptoms can be determined. Antibody application may be combined with the application of other substances, such as cell division inhibitors, growth factor inhibitors, cell cycle inhibitors, angiogenesis inhibitors, or other antibodies, to determine the synergistic efficacy and potential toxicity of the combination. To analyze toxic side effects mediated by the antibody, animals may be incubated with the antibody or control reagents, and symptoms potentially associated with tumor antigen-antibody therapy may be thoroughly investigated. Possible side effects of in vivo application of tumor antigen-antibody include toxicity, particularly in tumor antigen-expressing tissues. Antibodies that recognize tumor antigens in humans and other species, such as mice, are particularly useful for predicting potential side effects mediated by the application of monoclonal tumor antigen-antibody agents in humans.
[0456] Mapping of epitopes recognized by antibodies can be performed as described in the literature ["Epitope Mapping Protocols (Methods in Molecular Biology) by Glenn E. Morris ISBN-089603-375-9 and "Epitope Mapping: A Practical Approach" Practical Approach Series, 248 by Olwyn MR Westwood, Frank C. Hay].
[0457] The compounds and formulations described herein may be administered in the form of any suitable pharmaceutical composition.
[0458] The pharmaceutical composition is preferably sterile and comprises an effective amount of the antibody described herein and optionally an effective amount of an additive as discussed herein to produce a desired reaction or desired effect.
[0459] The pharmaceutical composition is generally provided in a uniform dosage and can be prepared in a known manner. The pharmaceutical composition may be in the form of, for example, a solution or a suspension.
[0460] The pharmaceutical composition may preferably comprise all pharmaceutically acceptable salts, buffering substances, preservatives, carriers, diluents, and / or excipients. The term "pharmaceutically acceptable" refers to the non-toxicity of substances that do not interact with the action of the active ingredient of the pharmaceutical composition.
[0461] Salts that are not pharmaceutically acceptable may be used to produce pharmaceutically acceptable salts and are included in the present invention. Pharmaceutically acceptable salts of this kind include, but are not limited to, those produced from acids such as hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, citric acid, formic acid, malonic acid, and succinic acid. Pharmaceutically acceptable salts may also be produced as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts, or calcium salts.
[0462] Buffering substances suitable for use in pharmaceutical compositions include acetic acid of salt, citric acid of salt, boric acid of salt, and phosphoric acid of salt.
[0463] Preservatives suitable for use in pharmaceutical compositions include benzalkonium chloride, chlorobutanol, parabens, and thimerosal.
[0464] Injectable formulations may include pharmaceutically acceptable excipients, such as Ringer lactate.
[0465] The term "carrier" refers to an organic or inorganic component of natural or synthetic nature, combined with an active ingredient to facilitate, enhance, or enable application. According to the present invention, the term "carrier" also includes one or more interchangeable solid or liquid fillers, diluents, or encapsulating materials suitable for administration to a patient.
[0466] Possible carrier materials for parenteral administration include, for example, sterile water, Ringer, Ringer lactate, sterile sodium chloride solution, polyalkylene glycol, hydrogenated naphthalene, and in particular biocompatible lactide polymers, lactide / glycolide copolymers, or polyoxyethylene / polyoxypropylene copolymers.
[0467] As used herein, the term "excipient" refers to any substance that may be present in a pharmaceutical composition and is not an active ingredient, such as, for example, carriers, binders, lubricants, thickeners, surfactants, preservatives, emulsifiers, buffers, fragrances, or colorants.
[0468] The formulations and compositions described herein may be administered by parenteral administration, including by injection or infusion, through any ordinary route. Administration may preferably be parenteral, for example, intravenously, intra-arterially, subcutaneously, between the skin layers, or intramuscularly.
[0469] Compositions suitable for parenteral administration generally comprise a sterile aqueous solution or a non-aqueous preparation of the active compound, which is preferably isotonic with the recipient's blood. Examples of compatible carriers and solvents include Ringer's solution and isotonic sodium chloride solution. Additionally, sterile fixative oils are generally used as the solution or suspension medium.
[0470] The formulations and compositions described herein are administered in an effective amount. "Effective amount" refers to an amount that achieves a desired response or desired effect, either alone or in combination with additional doses. When treating a specific disease or condition, a desired response is preferably related to the inhibition of the course of said disease. This includes slowing the progression of the disease, and in particular, hindering or reversing the progression of the disease. In the treatment of a disease or symptom, a desired response may also be the delay or prevention of the onset of said disease or said symptom. In particular, the term "effective amount" refers to a therapeutic amount sufficient to prevent the development, recurrence, or onset of cancer and one or more of its symptoms, to reduce the severity or duration of the cancer, to improve one or more of the symptoms of the cancer, to prevent the progression of the cancer, to induce regression of the cancer, and / or to prevent cancer metastasis. In embodiments of the present invention, the therapeutic amount is effective in achieving the stabilization, reduction, or elimination of cancer stem cell populations and / or the eradication, elimination, or control of primary cancer, metastatic cancer, and / or recurrent cancer.
[0471] The effective dose of the formulations or compositions described herein will depend on individual patient variables, including the condition to be treated, the severity of the disease, the patient's age, physiological status, size and weight, duration of treatment, type of concomitant therapy (if any), specific route of administration, and similar factors. Accordingly, the dose of the formulations described herein may be subject to the variability of these variables. If the patient's response is insufficient with the initial dose, a higher dose (or a higher dose achieved by a different, more localized route of administration) may be used.
[0472] The formulations and compositions provided herein may be used alone or in combination with conventional therapeutic regimens such as surgery, radiation therapy, chemotherapy, and / or bone marrow transplantation (autologous, syngeneic, allogeneic, or unrelated).
[0474] *The treatment of cancer is a field where combination strategies are particularly desirable because the combined action of two, three, four, or more anticancer agents / therapeutics often produces a much stronger synergistic effect compared to the effect of a single therapy approach. Accordingly, in other embodiments of the present invention, cancer treatments can be effectively combined with various other drugs. Among these are, for example, combinations of conventional tumor therapies, multi-epitope strategies, adjuvant immunotherapy, and therapeutic approaches targeting angiogenesis or programmed cell death (for review, refer, for example, to the literature [Andersen et al. 2008: Cancer treatment: the combination of vaccination with other therapies. Cancer Immunology Immunotherapy, 57(11): 1735-1743]). Sequential administration of different agents may inhibit cancer cell growth at different checkpoints, but different agents may inhibit, for example, neovascularization, survival or metastasis of malignant cells, or the conversion of cancer into a chronic disease.
[0475] The present invention is further illustrated by the following examples, which are not to be interpreted as limiting the scope of the invention.
[0476] Examples
[0477] Example 1: Technical Analysis of Genetic Immunopolymorphisms
[0478] Individual patterns of single nucleotide polymorphisms (SNPs) in the patient genome could predict the response rate of the therapeutic antibody IMAB362. To investigate these SNP patterns, genotypes were analyzed in all patients for a number of SNPs that play known or presumed roles in immune response and gastric cancer susceptibility.
[0479] In detail, the following questions were addressed.
[0480] a. SNP genotypes of all patients in relation to the studied polymorphisms.
[0481] b. Frequency of SNP genotypes in the patient population.
[0482] c. Identification of patients with polymorphisms that may directly interfere with the mechanism of action of IMAB362 (Fc receptor and complement system polymorphisms).
[0483] d. Accumulation of SNP genotypes per patient described as risk factors for gastric cancer susceptibility, cancer progression, or cancer treatment.
[0484] e. Correlation between SNP genotype and clinical outcomes.
[0485] f. Correlation between SNP genotype and progression-free survival (PFS).
[0486] Genetic polymorphisms were analyzed for all patients in Cohorts 1, 2, and 3. Patient blood samples were collected on Day 1 (V2a, pre-infusion).
[0487] Whole blood samples (9 ml, EDTA-Monovette) were collected from all patients. Immediately after sample collection at the research center at -20°C, the EDTA blood was stored in 1 ml fractions. The EDTA blood samples were shipped on dry ice (-70°C) and stored at -20°C. Upon arrival, the blood samples were immediately stored at -20°C until DNA isolation.
[0488] SNPs of interest were selected based on a literature review focusing on SNPs known to affect the function of the immune system, particularly those described as influencing the mechanism of action of therapeutic antibodies as Fc receptors and complement system polymorphisms. SNPs described as affecting cancer patient survival, susceptibility to (gastric) cancer, or the progression of gastric cancer were also selected and studied.
[0489] Genetic polymorphisms were analyzed using the SNP genetic analysis TaqMan™ assay (46 standard, 5 custom; Life Technologies) on the Fluidigm Biomark™ Real-Time PCR analysis platform. DNA isolation was performed according to standard protocols for isolating genomic DNA from whole blood. Using the Fluidigm Biomark™ Real-Time PCR analysis platform allows patient samples and specific SNP primers to be applied to a laboratory chip with 96 channels for patient DNA samples and 96 orthogonal channels for SNP analysis; thus, up to 96 patient samples can be genetically modified with 96 SNPs in a single measurement. Patient genomic DNA is pre-amplified by Specific Target Amplification (STA). The pre-amplified DNA was subjected to TaqMan™ Real-Time PCR analysis under standard conditions on the Fluidigm Biomark™ Real-Time PCR analysis platform. Allelic determination of SNPs for each patient and each analysis was performed using trademarked Fluidigm software and the statistical analysis software "R". Because the Fluidigm results were ambiguous, a subset of SNPs was identified using classical Sanger sequencing.
[0490] Genetic polymorphisms of 51 single nucleotide polymorphisms (SNPs) were determined for 53 patients. It was not possible to extract a sufficient amount of DNA from the blood sample of one patient to analyze SNPs. Six SNP genotypes determined a subgroup of only 20 patients. The genotype of the MDM2 SNP rs2279744 could not be determined in 9 patients due to technical issues. The results of the PTGS2 rs20417 genotype analysis for one patient were ambiguous and were not investigated further.
[0491] The determination of the SNP genotype matrix for the tested patients allows for statistical testing of changes in genotype frequency in the patient group compared to genotype frequencies in the Caucasian control group. The SNP genotype frequencies in the Caucasian control group are based on data collected by the International SNP Genotype Analysis Project (HapMap-CEU, PGA-EUROPEAN-PANEL, CAUC1, pilot_1_CEU_low_coverage_panel, CEU_GENO_PANEL, PDR-90) deposited in the public database dbSNP (National Center for Biotechnology Information, Bethesda (MD, USA)). The number of patients per genotype for a given SNP was compared to the number of patients per genotype in the Caucasian control group. The number of patients per genotype for the control group was calculated by multiplying the provided relative SNP genotype frequency of the population by the reported number of studied samples. This allowed for the identification of statistically significant differences between the patient group and the corresponding control group through a direct chi-square test.
[0492] Chi-square tests were performed on 48 of the 51 studied SNPs. Data on SNP genotype frequencies for SNPs C1QA (rs1044378), FCGR2C (Q57X (C->T)), and MDM2 (rs2279744) are not yet deposited in public databases. SNPs showing statistically significant changes in genotype frequency between patients and controls (5 of 48 SNPs, p<0.05) are shown in Figure 1.
[0493] Four of these five SNPs appear to play a role in cancer / gastric cancer susceptibility. All four cancer / gastric cancer susceptibility SNPs clearly show overrepresentation of their respective cancer-related genotypes in the patient population, as expected in gastric cancer patients (Table 1).
[0494] It has not been revealed until now that one of these five SNPs could be a risk / susceptibility factor for cancer or gastric cancer, rs12146727 (C1S). This SNP has so far only been listed as a presumptive risk factor for cardiovascular disease.
[0495]
[0496] Of the 51 SNPs studied in the patient population, 49 exhibit variant allelic patterns. This allows for testing changes in SNP allele frequencies among patient subgroups and, ideally, can aid in the identification of presumed responder populations. Only two SNPs, C1QA (rs1044378) and FCGR2C (AHN1ME8), exhibit invariant SNP genotypes across all patients, hindering the analysis of differentiation between different types. For the five SNPs, the principle that SNP allele frequencies depend on the composition of a given population is demonstrated, and statistically significant changes in allele frequencies can be determined by comparing them to the control group in this study. Therefore, the screening of tested SNPs is highly suitable for the future identification of SNP biomarker candidates.
[0497] Fc receptor and complement system polymorphisms can directly interfere with the IMAB362 mechanism of action. Genotypes for SNP alleles in genes that may affect the efficacy of antibody-based therapies in patients, such as FCGR3A (F176V[T→G], rs396991), FCGR2A (H131R [T→C], rs1801274), and C1QA ([276A→G], rs172378), were analyzed (Table 2).
[0498] The patient underwent additional genotyping for published SNP alleles of the FCGR2C gene (Q57X [C→T], rs no number) and complement factors C1S (R119H [G→A], rs12146727) and C1QA (rs292001, rs1044378). Although these SNPs have not yet been proven to affect antibody therapy, they were included as interesting candidate SNPs.
[0499] Table 2 shows patients with Fc receptor and complement system polymorphisms. The SNP genotypes of patients with well-documented Fc receptor and complement system polymorphisms are listed. The FCGR3A Val / Val polymorphism, which is presumed to have a positive effect on antibody therapy, is depicted in bold and underlined text. Polymorphisms in FCGR2A (Arg / Arg) and C1QA [G / G], which are presumed to have a negative effect on antibody therapy, are highlighted in gray shading and bold text.
[0500]
[0502] A total of 23 patients exhibit at least one well-documented Fc receptor and complement system polymorphism. Four patients (100411, 101120, 200336, and 400109) are homozygous for the FCGR3A allele (F176V [T→G]) and have been reported to increase response rates and progression-free survival with antibody therapy. Twelve patients are homozygous for the FCGR2A allele (H131R [T→C]), and an additional 10 patients are homozygous for the C1QA allele ([276A→G]). Both of these SNPs appear to have an adverse effect on antibody therapy. In total, a total of 21 patients are homozygous for the FCGR2A allele (H131R [T→C]) or the C1QA allele ([276A→G]) (patient 100511 is homozygous for both SNP alleles).
[0503] The correlation between the above results and the progression of the patient's disease can provide insights into the role of Fc receptors and complement system polymorphisms for IMAB362 therapy.
[0504] Disease progression and the efficacy of antibody therapy in patients may be influenced by the accumulation of SNPs listed as risk factors for gastric cancer susceptibility, cancer progression, or cancer treatment. Among the 51 SNPs investigated, 43 or fewer SNPs allowed for the categorization of each SNP genotype into 'risk' versus 'non-risk' genotypes. The number of homozygous SNP risk factor genotypes per patient was counted as they were generally listed as the most associated risk alleles. The relative frequency of the number of homozygous risk genotypes per patient in relation to the number of SNP risk factors investigated per patient is depicted in Figure 2.
[0505] Accumulation of 14 to 46% of investigated risk genotypes per patient is observed. This wide distribution prompts an investigation into whether the accumulation of SNP risk genotypes per patient is correlated with the patient's clinical outcomes.
[0506] In summary, 53 out of 54 patients were successfully genotyped for 51 SNPs. Of the 51 SNPs, 49 exhibit variant SNP allele patterns, enabling the analysis of patient subgroups for significant changes in SNP genotype frequencies. Homozygous Fc receptor and complement system polymorphisms, described as modulators of antibody therapy, were found in 23 out of 53 patients. An accumulation of 14 to 46% of investigated risk genotypes per patient is observed.
[0507] Example 2: Correlation between clinical results and SNP genetic trait analysis
[0508] The purpose of the correlation between genetic polymorphism genotypes and clinical outcomes is to identify putative SNP biomarker candidates that predict patient clinical outcomes. The putative biomarker candidates identified in this analysis will be validated in subsequent Phase IIb and Phase III studies. Validation of the putative biomarker candidates in Phase IIb will enable differentiation between the putative expected and predictive SNP candidates.
[0509] Correlation analysis for each SNP based on clinical results was performed independently on two defined Phase IIa clinical trial patient populations: the 'full Analysis set' (FAS) group consisted of 40 patients, and the 'protocol set' group consisted of 21 patients.
[0510] The absolute frequency of genotypes for each SNP in each clinical outcome group ('responders', 'non-responders') of the patient population was quantified using SAS Enterprise Guide 6.1. Absolute Genotype Frequency. The absolute genotype frequencies were organized into contingency tables (3x2 or 2x2) structured by clinical outcome and SNP genotype. The standard statistical test employed was Pearson's chi-square test. Where Pearson's chi-square test could not be used due to the numerical structure of the dataset, Fisher's exact test was applied in some cases for 2x2 contingency tables. The statistical significance level was p<0.05. Correlation analysis was performed using the statistical analysis software SAS Enterprise Guide 6.1.
[0511] To investigate the effect of SNP genotypes on progression-free survival, Kaplan-Meier curves were calculated for each group and formally compared using the statistical Logrank test. The statistical significance level was p<0.05. Logrank statistics were performed using the statistical analysis software SAS Enterprise Guide 6.1.
[0512] Correlation between clinical outcomes and SNP genetic analysis was performed to identify candidate SNP biomarkers for prognosis or prediction. Correlation was studied in two patient groups, an FAS group, and a PP group.
[0513] The FAS group comprises 40 patients, including 12 patients defined as 'responders' (clinical outcome 'partial remission' or 'safe disease') and 28 patients defined as 'non-responders' (clinical outcome 'disease progression'). As mentioned above, one patient sample from the FAS group (100801, non-responder) could not be used for SNP analysis, so the maximum number of FAS patients analyzed for correlation was reduced to 39. The PP group comprises 21 patients, including 10 responders and 11 non-responders.
[0514] The number of patients investigated per SNP differs, ranging from 20 to 39 (in the FAS group) and 20 to 21 (in the PP group).
[0515] Correlation analysis was performed as described above. Overall, 2 of the 51 SNPs studied showed statistically significant correlations with clinical outcomes in the PP group as well as the FAS group.
[0516] The two SNPs showing a statistical correlation between the clinical outcomes of the two groups and each SNP genotype are FCGR2A rs1801274 (p=0.0004 [PP]; p=0.008 [FAS]) and IL-10 rs1800896 (p=0.042 [PP], p=0.022 [FAS]) (Table 3). The number of statistically tested patients per SNP was 21 (PP) and 39 (FAS) for each of these two SNPs.
[0517]
[0518] As shown for DNMT3A rs1550117 [PP, p=0.035], SMAD4 rs12456284 [FAS, p=0.02], MUC1 rs4072037 (FAS, p=0.03), EGF rs4444903 [FAS, p=0.049], and CDH1 rs16260 [FAS p=0.049], five SNPs show a correlation with clinical outcomes in one patient population (FAS or PP) (Table 4).
[0519]
[0520] Testing for over- or under-labeling of SNP genotypes in responder / non-responder patients provides a scientific explanation for statistically significant frequency differences.
[0521] The genotypes of two SNPs, rs11615 (ERCC1) and rs396991 (FCGR3A), are correlated with extended progression-free survival (PFS) in the PP population (Table 5).
[0522]
[0523] The number of statistically tested patients per SNP was 21 (PP) and 39 (FAS) for each of the 9 listed SNPs.
[0524] FCGR2A rs1801274 [C / T]: In PP, all patients with the heterozygous rs1801274 [CT] genotype are responders (8 patients) reflected in the highly significant p-value (0.0004) of the statistical test. All PR patients (4 out of 4) exhibit this genotype. Most non-responders (73%, 8 out of 11) exhibit the homozygous [TT] genotype (Table 6). This genotype distribution pattern can also be found in the FAS population, although not as distinct as in the PP population (Table 7). Additionally, in the FAS population, a significant number of non-responder patients also have the [CT] genotype (30%), which is less prominent but still leads to a statistically highly significant p-value.
[0525]
[0526]
[0527] Survival Analysis FCGR2A rs1801274 [C / T]: The highly significant overrepresentation of the rs1801274 genotype [CT] in the responder population is expected to be reflected in the highly significant correlation with extended progression-free survival (PFS). Indeed, in both groups of PP (Fig. 3) and FAS (Fig. 4), the [CT] genotype is correlated with extended PFS (PP p=0.0007, FAS p=0.03). It is important to note that during the first 60-day treatment period, FAS patients with the [TT] genotype tend to have a higher PFS rate than patients with the [CC] or [CT] genotypes. Therefore, through survival analysis, rs1801274 (FCGR2A) was identified as a highly interesting candidate for an putative biomarker with predictive or prognostic characteristics.
[0528] IL-10 rs1800896 [A / G]: In PP, there were no patients with the homozygous rs1800896 [GG] genotype among non-responder patients (Table 8). This genotype was found at a high frequency (40%) in responder patients (4 out of 10). Only 1 out of 10 responders (10%) showed the [AA] genotype, and the remaining responders showed the heterozygous [GA] genotype. In FAS, a comparable genotype frequency distribution can be observed (Table 9), but the [GG] genotype can be observed at a low frequency (11%, 3 out of 27) in non-responder patients in this group.
[0529]
[0530]
[0531] Survival Analysis rs1800896 (IL-10) [A / G]:The rs1800896 [GG] genotype was significantly overrepresented in responder patients. The statistical correlation between PFS and the [GG] genotype showed that the [GG] genotype was not significantly correlated with PFS in the PP and FAS populations (PP p=0.27 (Fig. 5); FAS p=0.08 (Fig. 6)). However, the p-value for the FAS survival correlation is limited to significance, which may be an indication that significance can be reached in larger populations with reduced statistical noise. Overall, rs1800896 (IL-10) is an interesting candidate for an putative biomarker.
[0532] DNMT3A rs1550117 [G / A]: In PP, 4 responders (40%) showed the [GA] genotype, while all non-responders showed the [GG] genotype (p=0.03, Table 10).
[0533]
[0534] Survival Analysis rs1550117 (DNMT3A) [G / A]: The rs1550117 [GA] genotype was significantly overrepresented in responder patients of the PP group. In the FAS group, the difference in PFS between [GA] and [GG] carriers is borderline significant (FAS p=0.058) (Fig. 7).
[0535] In the FAS population, only one patient has a carrier of the [AA] genotype.
[0536] SMAD4 rs12456284 [G / A]: In FAS, a statistically significant overrepresentation of the [GA] genotype (7 out of 12 patients, 58%) compared to the [AA] and [GG] genotypes can be found in the responder population (p=0.023, Table 11). In the FAS non-responder population, the frequency of the [GA] genotype can be found at a frequency of 19% (5 out of 27 patients were non-responders). In the PP population, this association is indicated by a significant trend (p=0.081, data not shown).
[0537]
[0538] Survival Analysis rs12456284 (SMAD4) [G / A]: The rs12456284 [GA] genotype is significantly overrepresented in FAS responders and shows the same trend in PP responders. Regarding the statistical correlation between PFS and the rs12456284 genotype, the [GA] genotype in the PP group is significantly correlated with PFS (PP p=0.048) using the Gehan-Brelow-Wilcoxon test (Fig. 8), whereas the significance using the log-rank test is p=0.35. The Gehan-Brelow-Wilcoxon test places more weight on PFS cases at earlier time points than the log-rank test, and indeed, the difference between [GA] and [AA] carriers is most pronounced during the first 100 days of each of these Phase IIa clinical trials. In the FAS population, the [GA] genotype suggests a tendency for [GA] carriers toward extended PFS based on visual inspection, but there is no significant correlation with PFS (p=0.20 (logrank), p=0.23 (Gehan-Brelow-Wilcoxon)).
[0539] MUC1 rs4072037 [A / G]: In FAS, the rs4072037 genotype [AA] was found with the highest frequency of 67% in the responder group (8 out of 12), whereas only 26% of non-responders exhibited this genotype (7 out of 27). None of the responder patients exhibited the homozygous [GG] genotype (Table 12), whereas non-responders showed the [GG] genotype at a rate of 22% (6 out of 27). These differing genotype distributions in responder and non-responder FAS patients were statistically significant (p=0.03). A comparable genotype distribution pattern is found in the PP group, where responders exhibit a relative [AA] genotype frequency of 70% (7 out of 10), which is nearly identical to that in the FAS group (significance of trend p=0.11) (data not shown).
[0540]
[0541] Survival Analysis rs4072037 (MUC1) [A / G]: Significant overrepresentation of the rs4072037 genotype [AA] in responder patients may indicate a correlation between this genotype and PFS. Statistical tests indicate that the [AA] genotype is significantly correlated with PFS in the PP and FAS populations (PP p=0.001, (Fig. 9); FAS p=0.02, (Fig. 10)). This survival analysis identified rs4072037 (MUC1) as a very interesting candidate for a prognostic or predictive biomarker.
[0542] EGF rs4444903 [G / A]: In FAS, the rs4444903 genotype [AA] was significantly overrepresented in the responder group (5 out of 12, 42%) compared to the non-responder group (3 out of 27, 11%) (p=0.049) (Table 13). In the PP group, this asymmetric distribution was not statistically significant (p=0.32, data not shown).
[0543]
[0544] Survival Analysis rs4444903 (EGF) [G / A]: The correlation between PFS and the rs4444903 [AA] genotype in the PP or FAS populations was not statistically significant (FAS p=0.1; PP p=0.16). However, a trend toward prolonged PFS can be observed in both the PP and FAS populations (Fig. 11).
[0545] CDH1 rs16260 [C / A]: In FAS, the rs16260 genotype [AA] was found at a significantly higher frequency in responders (5 out of 12, 42%) than in the non-responder group (3 out of 27, 11%) (p=0.049, Table 14). In PP, this asymmetric distribution between the two patient groups was not significant (p=0.72, data not shown).
[0546]
[0547] Survival Analysis rs16260 (CDH1) [C / A]:The correlation between PFS and rs16260 (CDH1) genotype [AA] is borderline statistically significant in the FAS population (log-rank test p=0.065, Gehan-Brelow-Wilcoxon test p=0.032) (Fig. 12).
[0548] ERCC1 rs11615 [C / T]: In the PP, a tendency for a high frequency of the rs11615 genotype [TT] in the responder population (3 out of 10, 30%) was found (p=0.068; non-responder population (0%)). In contrast, the homozygous [CC] genotype was found only in the non-responder population (2 patients) (Table 15).
[0549]
[0550] Survival analysis rs11615 (ERCC1) [C / T]: The rs11615 [TT] genotype is found exclusively in the responder population of the PP group. The statistical correlation between PFS and the rs11615 genotype in PP shows that the rs11615 genotype is highly significant with PFS, and [CT] and [TT] carriers demonstrate extended survival rates compared to the [CC] carrier (PP p=0.0001) (Fig. 13). Despite this significant value, it should be noted that there are only 2 individuals with the [CC] genotype and 3 with the [TT] genotype in PP. However, if the effect is valid in a patient population with a larger effect, there is a tendency for the same effect to be observed in the FAS group (FAS p=0.13, data not shown).
[0551] Survival Analysis FCGR3A rs396991 [T / G]:In PP or FAS, the genotype of SNP rs396991 is associated with clinical outcomes (FAS p=0.49; PP p=0.29, data not shown). However, survival analysis in the PP group showed high statistical significance in that patients with genotypes [TG] and [TT] exhibited improved PFS compared to [GG] (p=0.0007, Fig. 14). Additionally, this effect can be observed in the FAS group as well (p=0.25; data not shown). Despite the significant values obtained for the PP group, it should be noted that only 3 PP patients were [GG] carriers.
[0552] Example 3: Discussion of accompanying immunopolymorphism analysis
[0553] The primary objective of this Phase IIa clinical trial was to evaluate the safety and efficacy of IMAB362, a therapeutic anti-CLDN18.2 mononuclear antibody, in patients with gastroesophageal adenocarcinoma. Additionally, a companion analysis of genetic immune response polymorphisms was performed to evaluate parameters that could serve as potential predictive or prognostic biomarkers in relation to IMAB362 treatment.
[0554] Discussion on the described immunopolymorphism analysis
[0555] Genetic polymorphisms in the patient genome have been shown to alter the response rate of therapeutic antibodies. To investigate the impact of individual genetic variations on response rates, we determined the genotypes of 51 single nucleotide polymorphisms (SNPs) that play known or presumed roles in immune response and gastric cancer susceptibility or progression in patients.
[0556] In this study, 51 SNPs were genotyped in 53 of the 54 patients successfully studied. Statistically significant changes in genotype frequency in the patient group compared to the control group were detected for 5 SNPs. Four of these SNPs had previously been shown to be associated with cancer / gastric cancer susceptibility. Each of these 4 cancer / gastric cancer-associated genotypes was over-expressed in the study group, as expected in the patient group with late-stage GC. The over-expression of each homozygous genotype may indicate a recessive mode of action suggesting attenuated gene function, as opposed to enhanced gene activity. This is highlighted in published data; for example, the gastric cancer-associated AA genotype of SNP rs16260 in CDH1 has been reported to cause downregulation of CDH1 expression due to its location in the CDH1 promoter at -160.
[0557] Even though these polymorphisms had not previously been listed as risk factors for gastric cancer, polymorphisms in genes related to immune signaling were investigated. Genetic polymorphisms in genes encoding immune signaling factors were found to significantly moderate the risk of developing gastric cancer. Therefore, the response rate of antibody-based cancer therapy may also be influenced by these SNPs.
[0558] The over-labeled IL-2 genotype GG (SNP rs2069762) in the patient population is H. pylori It is associated with an increased risk of infection-induced gastric atrophy and may be susceptible to gastric cancer. The CTLA4 SNPs rs231775 and rs2274223 (PLCE1) genotypes are listed as risk factors for GC susceptibility. As for published studies on rs231775, there are inconsistencies in the genotype sequences, but no conclusions will be presented here.
[0559] In this study, Fcγ-receptor and complement system polymorphisms were investigated. An arbitrary beneficial FCGR3A genotype encoding Val / Val [GG] was detected in 4 APT patients, and a potentially adverse FCGR2A genotype (Arg / Arg) [CC] was detected in 12 APT patients.
[0560] As a second-effect mechanism, CDC has been shown to be influenced by SNP polymorphisms: the allele carrier of a polymorphism in complement component C1qA ([276A->G], rs172378) shows a prolonged response after rituximab treatment for follicular lymphoma. A complement system polymorphism in C1QA with genotype 'GG' was detected in 10 patients and may influence any adverse response. However, the SNP polymorphism rs12146727 in complement component C1S has so far only been described in antibody therapy or cancer-independent screenings.
[0561] The identification of significant changes in genotype frequency between patient and control groups demonstrates that changes in SNP genotype frequency can be used as predictive and prognostic markers in clinical studies.
[0562] The accumulation of SNP risk alleles can also affect patient clinical outcomes. To enable this analysis, the number of homozygous SNP risk genotypes was calculated for each patient. The correlation between these figures and treatment response can provide insights into the role of SNP risk factor accumulation.
[0563] Discussion on the correlation between SNP genetic analysis and clinical outcomes
[0564] FCGR2A rs1801274:
[0565] Testing for over- or under-represented FCGR2A genotypes indicates that in the PP population, all patients with the heterozygous rs1801274 genotype [CT] are responders, and that patients with partial response (PR) possess this genotype exclusively. In the non-responder population, the over-represented homozygous genotype is [TT]. Simple observation of these frequency distributions cannot draw conclusions as to whether the [CT] genotype is beneficial or [TT] is adverse. In most studies investigating the effects of SNP genotypes, each homozygous genotype exhibits the most potent biological effect and, in contrast to enhanced gene activity, often displays a recessive mode of action reflecting the weakened gene function of both alleles. When SNP alleles induce increased genetic activity, a stepwise effect of the biological effect can often be observed: one allele (i.e., heterozygous) increases gene activity, and two alleles (i.e., homozygous) further increase gene activity. In both cases of gain or loss of function, the most potent biological / clinical effects are observed in patients with the homozygous genotype. Under this assumption, overrepresentation of the homozygous [TT] genotype in the non-responder population in the PP and FAS populations will lead to adverse results.
[0566] However, this was unexpected, as the rs1801274 FCGR2A [TT] genotype has been described in many clinical studies as a factor that prolongs PFS. In our Phase IIa clinical trial, a close investigation into the association between genotype and PFS in non-FAS responder patients revealed that FAS PD patients with the [TT] genotype showed a tendency for actually increased PFS time during the first 60 days of treatment, in contrast to FAS PD patients with the [CT] genotype (compare Table 7 and Figure 4). Interpretations based on these observations, consistent with the underrepresentation of [TT] in responders with prolonged PFS, may involve the overlap of two different molecular mechanisms: first, the rs1801274 [CT] genotype may be a marker for responder patients. This is a novel observation not previously described in the literature and suggests that this genotype is a predictive marker for IMAB362 treatment. The molecular mechanism underlying this novel observation has not yet been resolved.
[0567] A second observation, already described in the literature on other therapeutic anticancer antibodies, is likely the prolonged PFS in patients with the FCGR2A [TT] genotype. In our Phase IIa clinical trial, this effect is attributed to the overlap with the first hypothesized mechanism, which is observed only as a tendency in non-responder patients. Mechanistically, the second observation can be explained by the increased binding affinity of the IgG1 antibody to the FCGR2A 131 His / His receptor allele (encoded by the [TT] genotype), in contrast to the weak binding affinity to the homozygous FCGR2A 131 Arg / Arg receptor allele (encoded by the [CC] genotype): In a systematic study investigating the effects of Fcγ-receptor polymorphisms, it was recently revealed that IgG1 isomorphic antibodies actually bind with different affinities to the two allelic forms of Fcγ receptor IIA, such as H131, which has a higher affinity than R131. It is hypothesized that different affinities of IgG antibodies for FFCGR2A receptor alleles generally affect the triggering rate of effector mechanisms and, consequently, prolong PFS in patients possessing these receptor alleles. Data supporting this hypothesis are provided by reports indicating that Fcγ-receptor polymorphisms FCGR2A H131R and FCGR3A F176V (Phe > Val, rs396991) may affect the clinical efficacy of trastuzumab-based IgG1 antibody therapy in patients with metastatic breast cancer. Patients with genotypes FCGR3A 176 Val / Val and FCGR2A 131 His / His demonstrated significantly better response rates and progression-free survival. The same polymorphisms are also associated with response rates in rituximab (IgG1)-treated patients with B-cell lymphoma. In another study, prolonged PFS after cetuximab (IgG1) therapy may be associated with the FCGR3A 176 Val / Val genotype.
[0568] Although controversial, there are recent strong studies reporting no association between Fcγ-receptor polymorphisms and survival rates, response rates, or progression-free survival of the antibodies discussed. In the Breast Cancer International Research Group (BCIRG) BCIRG-006 trial, 1,218 patients were treated in a randomized study with two trastuzumab-containing arms and a non-trastuzumab control arm. No association could be confirmed between the Fcγ-receptor polymorphisms reported above and trastuzumab efficacy. In a long-term study of 460 patients receiving rituximab in combination with chemotherapy for follicular lymphoma, no association between Fcγ-receptor polymorphisms and progression-free survival was reported. In the REACH trial of 419 patients treated with fludarabine and cyclophosphamide (FC) or rituximab plus FC, FCGR2A and FCGR3A polymorphisms did not significantly affect outcomes. Recent cetuximab trials also did not recommend Fcγ receptor polymorphism as a useful biomarker and obtained inconsistent results. This may reflect intrinsic population factors or differences in concurrent chemotherapy.
[0569] MUC1 rs4072037:
[0571] MUC1 is a transmembrane glycoprotein of the mucin family. Mucin is a high-molecular-weight protein containing oligosaccharide and n-glycan chains, extensively O-glycosylated in the N-terminal extracellular domain. Mucin is expressed on the inner layer of the epithelium and on the anterior surfaces of ducts in the respiratory and gastrointestinal tracts, as well as in the liver, pancreas, and kidneys. Transmembrane mucin spans the membrane as a single α-helical and, along with their sugar chains, provides a protective inner layer in the extracellular space. Mucin secreted into the extracellular space forms a mucinous gel layer that serves as additional physical protection for the epithelium.
[0572] Transmembrane MUC1 and secreted mucins MUC5C and MUC6 are the major mucins expressed in the stomach. MUC1 is translated as a single polypeptide chain subject to self-cleavage. The N-terminal extracellular domain (MUC1-N) initially remains non-covalently bound to the transmembrane / cytoplasmic domain (MUC1-C). This cytoplasmic domain acts as a signaling domain that can be associated with various transcription factors that engulf the nucleus and directly activate gene expression. Cellular stress can induce proteolytic cleavage of the MUC1-N and MUC1-C domains through the secondary proteolytic site. This can be observed in cancer cells where MUC1 is no longer expressed in an aligned manner at the cell's tip membrane, but it can also be found to be overexpressed and localized throughout the cell. The release of the extracellular domain (also known as CA15-3) into the extracellular space and the intracellular localization of MUC1-C are the results. Cytoplasmic signaling domains act as oncogenes, for example, by activating Wnt / β-catenin signaling and blocking apoptotic pathways.
[0573] However, the extracellular domain of MUC1 is not only a static structural component but also plays a crucial role in signaling processes at the cell membrane. Glycosylation and expression status of the MUC1 extracellular domain have been shown to regulate the interactions between membrane signaling molecules and extracellular substrates. In tumor cells, hypoglycosylated MUC1-N has been reported to increase signaling between membrane molecules such as ICAM-1 or E-selectin and the MUC1 core protein. Furthermore, mucin expression and glycosylation status appear to mask membrane-associated molecules. In cancer cells, masking of the HER2 protein by mucin expression has been described as a possible resistance mechanism to trastuzumab treatment.
[0574] The MUC1 polymorphism rs4072037 'A' allele has been described as a risk factor for gastric cancer susceptibility. This polymorphism is a G→A exchange in exon 2 that results in selective splicing of MUC1 at the predicted signal peptide cleavage site. The failure of the signal peptide to cleave leads to abnormal localization or glycosylation patterns of the MUC1 protein, which can consequently result in a deficiency of protein function.
[0575] In these Phase IIa clinical trials, the rs4072037 [AA] genotype was found to be statistically associated with the responder population. It can be inferred that the hypoglycosylated or under-labeled [AA] allele forms of MUC1 enable good access of IMAB362 to the membrane target molecule CLDN18.2 expressed in cancer cells, thereby enhancing therapeutic efficacy. This would make rs4072037 a predictive biomarker.
[0576] IL-10 rs1800896:
[0577] IL-10 is an important regulator of the immune system with pleiotropic functions. IL-10 is known to act as an anti-inflammatory and immunosuppressive cytokine by inhibiting macrophage-dependent antigen-specific T cell proliferation and macrophage-dependent production by T cells. However, IL-10 has also been described as an immunostimulatory cytokine that enhances the differentiation and growth of B-cells, granulocytes, and mast cells, as well as NK cell and CD8+ T cell activation. The pleiotropic potential of IL-10 is also reflected by its broad expression in many immune cell types, including Th2 cells, Treg cells, Th3 cells, NK T cells, B cells, macrophages, and dendritic cells. This dual role of IL-10 is reflected in its tumor-suppressing potential as well as its tumor-promoting potential: IL-10 secreted by tumor cells infiltrating immune cells as macrophages or by tumors enables tumor cells to evade immune surveillance, which has only been partially elucidated. One described mechanism involves Treg cells contributing to the induction of peripheral tolerance through the expression of immunomodulatory cytokines such as IL-10. Another reported mechanism involves inhibiting the cross-presentation of tumor-associated antigens by dendritic cells, thereby preventing T cells from initiating an effective immune response against tumor cells. On the other hand, exposing malignant tumor cells to IL-10 leads to the downregulation of HLA class I proteins, increasing the sensitivity of NK cells to cytotoxicity.
[0578] As the 'G' allele has been reported as a risk factor for gastric cancer and renal cancer, the IL-10 promoter polymorphism rs1800896 at position (-1082) is important. Compared to the 'A' allele, IL-10 expression of the 'G' allele of this polymorphism is In vitroIt has been reported to be associated with a decrease. In responder patients of this Phase IIa clinical trial, the [GG] genotype of rs1800896 may be overrepresented, possibly indicating low relative expression levels of IL-10. It can be hypothesized that patients with the [GG] genotype have low IL-10 expression, which may make it more difficult for tumor cells to escape immune surveillance by one of the aforementioned mechanisms. In fact, none of the 12 FAS responder patients showed elevated IL-10 serum levels, in contrast to 22% of FAS non-responder patients (measured as 6 out of 27). However, other authors describe the 'A' allele as being associated with reduced IL-10 expression.
[0579] Furthermore, it should be noted that IL-10 is signaled via the intracellular mediator Stat3, and Stat3 activation depends on MUC1-C. Therefore, the functional interaction between MUC1 and IL-10 may explain why these molecules proved to be statistically significant biomarker candidates in these Phase IIa clinical trials. Finally, FCGR2A is often expressed in macrophages, which are the primary source of IL-10 in the tumor microenvironment. If these putative biomarker candidates gain prominence in ongoing and future studies, investigating the functional interactions of these factors will be quite interesting.
[0580] rs1550117 (DNMT3A):
[0581] rs1550117 is an SNP in the DNMT3A gene encoding DNA (cytosine-5)-methyltransferase 3A, an enzyme that catalyzes the transfer of methyl groups from DNA to specific CpG structures, inducing epigenetic modification. The genotype [AA] has been shown to increase the risk of gastric cancer compared to [GG] or [GA]. In this study, [AA] was detected in only one patient in the FAS group and was not detected in any patients in the PP group. Furthermore, this may indicate that [AA] confers survival risk, thereby preventing third and fourth-line treatments with [AA] carriers in these Phase IIa clinical trials. The fact that [GA] is significantly correlated with clinical outcomes in PP suggests that this marker holds potential as a predictive biomarker for IMAB362 treatment.
[0582] rs12456284 (SMAD4):
[0583] rs12456284 is an SNP in the SMAD4 gene encoding the "maternal to decapentaplex homolog 4," an intracellular TGFβ / BMP signaling co-transducer. It has been reported that the [GG] genotype significantly reduced the risk of gastric cancer. The statistically significant overrepresentation of the heterozygous [GA] genotype compared to the [AA] genotype in the FAS responder population suggests that this genotype may serve as a predictive biomarker. This is supported by the extended PFS of patients in the PP population with [GA].
[0584] rs4444903 (EGF):
[0585] Although the functional polymorphism rs4444903 in the promoter region of the EGF gene was observed to regulate EGF protein levels, a larger amount of EGF factor was detected in the serum of [GG] carriers. The G allele of this polymorphism and the [GG] genotype showed a significant correlation with an increased risk of gastrointestinal cancer in a meta-analysis.
[0586] In these Phase IIa clinical trials, genotype [AA] was significantly overrepresented in FAS responders, and patients with this genotype showed a tendency for prolonged PFS in the FAS and PP populations. This suggests that the rs4444903 [AA] genotype may be a predictive or prognostic biomarker.
[0587] rs16260 (CDH1):
[0588] The cell adhesion protein Cadherin 1 (E-cadherin) is a member of the calcium-dependent cadherin superfamily. Loss of function is associated with cancer progression. The rs16260 [A] allele of the CDH1 promoter has been shown to reduce the transcriptional efficiency of Cadherin 1. Additionally, the -160A allele of CDH1 has been described as a susceptibility factor for gastric cancer development.
[0589] In this study, the rs16260 [AA] genotype carrier was statistically overrepresented in FAS responders. This may suggest that the [AA] genotype is an estimated predictive biomarker.
[0590] rs11615 (ERCC1) and rs396991 (FCGR3A):
[0591] Two SNPs, rs11615 (ERCC1, DNA repair protein "resection repair cross-complementation group 1") and rs396991 (FCGR3A, low affinity immunoglobulin gamma Fc region receptor III-A), show a correlation between extended PFS and genotype (ERCC1 [TT], FCGR3A [TG] and [TT]). This suggests that these SNPs may be predictive or prognostic biomarkers.
[0592] Description of the deposit of microorganisms or biological material (PCT Rule 13 bis )
[0593]
[0594] New international application
[0595] Ganymed Pharmaceuticals AG, et al.
[0596] Method and composition for predicting the therapeutic efficacy and cancer prognosis of cancer treatments
[0597] Office No.: 342-85 PCT
[0598] Attachment regarding biological substances
[0599] Additional entry regarding deposit details:
[0600] 1) The name and address of the trustee institution for the entrusted items (DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748) are:
[0601] It is DSMZ-German Culture Center for Microorganisms (Germany 38124 Braunschweig Maaszeroder Weg 1b).
[0602] 2) The name and address of the trustee institution for the entrusted materials (DSM ACC2808, DSM ACC2809, DSM ACC2810) are:
[0603] It is DSMZ-German Culture Center for Microorganisms (7B, Inhofenstrasse, Braunschweig, 38124, Germany).
[0604]
[0605] Additional details regarding all deposits mentioned above
[0606] - Mouse (Mus musculus) myeloma P3X63Ag8U.1 fused with mouse (Mus musculus) spleen cells
[0607] - Hybrid cells that secrete antibodies against human claudin-18A2
[0608] 3) Depositor:
[0609] All deposits mentioned above were made by Ganymed Pharmaceuticals AG (Germany 55131 Mainz Freiligratstrasse 12).
[0610] 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2737 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2738 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2739 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2740 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2741 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2742 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2743 수탁일자 : 2005-10-19 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2745 수탁일자 : 2005-11-17 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2746 수탁일자 : 2005-11-17 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2747 수탁일자 : 2005-11-17 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2748 수탁일자 : 2005-11-17 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2808 수탁일자 : 2006-10-26 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2809 수탁일자 : 2006-10-26 기탁기관명 : DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 수탁번호 : DSMZDSMACC2810 수탁일자 : 2006-10-26
Claims
Claim 1 A method for evaluating whether a cancer patient having a tumor antigen-positive tumor is a responder to antibody therapy against the tumor antigen, wherein the tumor antigen is the CLDN18.2 protein and the tumor is a gastroesophageal tumor or a metastatic tumor thereof, and the method comprises determining the genotype for one or more single-nucleotide polymorphisms selected from the group consisting of FCGR2A rs1801274 and FCGR3A rs396991 in a sample obtained from said patient, wherein the presence of the following genotypes indicates a reduced risk that the cancer patient is not a responder to said antibody therapy: (a) the presence of a heterozygous FCGR2A rs1801274 [CT] genotype; (b) the presence of a heterozygous FCGR3A rs396991 [TG] genotype; and (c) the presence of a homozygous FCGR3A rs396991 [TT] genotype. Claim 2 In claim 1, the antibody mobilizes the patient's immune system to destroy tumor cells. Claim 3 A method according to claim 1, wherein the antibody acts through antibody-dependent cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC). Claim 4 The method of claim 1, wherein the antibody comprises a heavy chain comprising an amino acid sequence represented by SEQ ID NO. 17 or 51 or a fragment thereof and a light chain comprising an amino acid sequence represented by SEQ ID NO. 24 or a fragment thereof. Claim 5 The method according to claim 2, wherein the antibody comprises a heavy chain comprising an amino acid sequence represented by SEQ ID NO. 17 or 51 or a fragment thereof, and a light chain comprising an amino acid sequence represented by SEQ ID NO. 24 or a fragment thereof. Claim 6 A method according to any one of claims 1 to 5, wherein the tumor is an advanced adenocarcinoma of the stomach or lower esophagus.
